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Abstract 
Physician’s compliance with Essential Drug List (EDL) is defined as the extent to which their 
prescribing behavior matches the recommendations of the Palestinian Ministry of Health. 
Improper prescribing behavior of physicians has a negative impact on medical resources leading 
to serious financial overload, as well as undesired health impacts on patients. Promoting 
appropriate use of drugs, including compliance with EDL could save up to 5% of countries 
health expenditures. The WHO defines the Essential Drugs as those that satisfy the priority 
health care needs of the population.   
The overall aim of the study was to assess physicians’ compliance with EDL at governmental 
hospitals in the GG. The design of this study is a cross section: quantitative analytical design.  
The quantitative data were collected using 2 tools: First tool was a well-structured questionnaire 
which was used to collect data on physicians’ knowledge and attitude toward EDL. The other 
tools are three checklists that were used to collect data on Physicians’ compliance with EDL. The 
first checklist was used to extract data from the in-patient medication sheets (admitted cases); the 
second checklist was used to extract data from the emergency department reports-discharge 
sheet of emergency rooms; and the third checklist was used to extract data from the in-patient 
discharge reports, discharge certificate in the study settings.  In total, 296 questionnaires were 
collected, 1098 in-patient medication sheets, 1595 emergency department reports, and 1226 in-
patient discharge reports from the study settings. Analysis of data was conducted using SPSS 
program; the analysis involved conducting frequency distributions, cross tabulation, mean 
percentages, one-way Anova, and Chi-square. 
Findings of the study have showed that the average total number of drugs prescribed in the in-
patient medication sheet in the study settings was 5.21 drugs per sheet; the majority of the 
collected in-patient medication sheets (78%) were fully compliant with EDL. The average total 
number of drugs prescribed in the emergency department reports among the study settings was 
2.17 drugs per emergency department report; only one third of the collected emergency 
department reports (31%) were fully compliant with EDL. The average total number of drugs 
prescribed in the in-patient discharge reports among the study settings was 3 drugs per report; 
nearly one third of the collected in-patient discharge reports (31%) were fully compliant with 
EDL. The findings of the study have also shown that knowledge of the study participants about 
the MoH-EDL, hospital EDL and its updating process is not high. However, there is a positive 
attitude among physicians about the EDL and its benefits. The majority of the study participants 
agreed on the importance and necessity of EDL for: provision of equitable health services; 
provision of quality health services; reduction of wasting in financial resources; reducing patient 
harm; and on the fact that the listed drugs in the EDL are selected on scientific bases. The 
majority of the study participants neither communicated with hospital pharmacists properly nor 
responded to pharmacists’ recommendations in prescribing drugs from EDL. The study findings 
revealed that hospital management does not efficiently exercising its role in encouraging 
physicians to be compliant with EDL.  
There is a need to implement a continuous education and training programs for healthcare staff 
concerning EDL and treatment protocols; to disseminate printed and softcopies copies of the 
EDL and hospital EDL; to activate the monitoring role of auditing system to improve physicians’ 
compliance with EDL; to update the MoH EDL and hospital EDL. There is a need to conduct 
more research studies, including both qualitative and quantitative studies to deeply understand 
all the relevant factors that might affect physicians’ compliance with EDL. There is also a need 
to conduct similar research studies in specialized and private hospitals. 
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Chapter (1) 
Introduction 
1.1. Background 
Access to health care is a fundamental human right and the attainment of the highest possible 
level of health is one of the most important world-wide social goals (Declaration of Alma Ata, 
1978). Health systems are considered the corner stones in preventing and treating diseases. 
According to World Health Organization (WHO), a well-functioning healthcare system should 
improve the health status of the population, defend them against what threatens their health, 
protect against the financial consequences of illnesses, provide equitable access, and make it 
possible for people to participate in decisions affecting their health (WHO, 2010a). 
  Health system is composed of six building blocks: leadership and governance, health 
information system, health financing, human resource for health, service delivery, and 
affordable essential medical products (WHO, 2010a). According to WHO, medical products 
should have a regulatory system, national essential lists, treatment protocols, a good supply 
and distribution system, a drug availability and price monitoring system, and  a rational use 
promoting programs (WHO, 2010a). According to WHO, the proportion of health dollars 
spent on pharmaceuticals is about 20% in developed countries, 15 to 30% in transitional 
countries, and 25 to 66% in developing countries (WHO, 2013a). Economically, spending on 
drugs is the largest public expenditure on health after personnel costs in low income countries 
(WHO, 2013a)   
Horne (2005) defined compliance as the extent to which behavior matches the 
recommendations. Barriers for good compliance include lack of enough time and physicians' 
lack of knowledge, awareness, or disagreement with specific guidelines (Sequist et al., 2005). 
According to Fisher (2012), there is no universal compliance program that could fit all 
systems. Fisher (2012) has proposed seven basic core elements for effective compliance 
program including: adoption of written guidelines and policies; identification and appointment 
of compliance officer; establishment of anonymous reporting systems;  presence of effective 
education and training programs; presence of auditing systems;  presence of mechanisms to 
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enforce the  compliance program requirements; and presence of an ongoing system of program 
modification based upon audit, feedback and experience (Fisher, 2012). 
More than 50% of all drugs worldwide are prescribed, dispensed, or sold inappropriately, 
while 50% of patients fail to take them correctly (WHO, 2013a). Moreover, about one third of 
the world‘s population lacks access to essential drugs (WHO, 2013a). These essential drugs 
are selected not only with due regard to their public health relevance; evidence of efficacy, 
safety, and comparative cost–effectiveness; but also with regard to many factors, such as the 
pattern of prevalent diseases, treatment facilities, training and experience of available 
personnel, financial resources, genetic, demographic, and environmental factors (WHO, 
2013b). The public health relevance criteria of a drug include incidence and prevalence of the 
disease, burden of disease, region-specific needs, evidence of potential impact or high 
effectiveness and potential political impact of identifying a drug as essential for advocacy 
purposes (WHO, 2013b). 
EDL is intended to include drugs that are available within the context of functioning health 
systems at all times in adequate amounts, in the appropriate dosage forms, with assured 
quality, and at a price the individual and the community can afford (Kar et al., 2010). As a 
general concept, EDL is intended to be flexible and adaptable to many different situations; 
adding items to it or deleting items from it remains a national responsibility (Kar et al., 2010). 
Careful selection of a limited range of essential drugs results in a higher quality of care, better 
drug chain management (including improved quality of prescribed drugs), and a more cost-
effective use of available health care resources (Kar et al., 2010; WHO, 2002b). 
1.2. Importance of the study 
As aforementioned, health expenditure represents one of the largest portions of expenditure, 
globally it is about 5.3 trillion US$ (WHO, 2010b). At a conservative estimate, 20–40% of 
health resources are being wasted (WHO, 2010c). Medicines account for three of the most 
common causes of inefficiency. Inefficiencies can sometimes be due to insufficient, rather 
than too much, spending on health (WHO, 2010c). Improper prescribing behavior of 
physicians has a negative impact on medical resources leading to serious financial overload, as 
well as undesired health impacts on patients. Promoting appropriate use of drugs, could save 
up to 5% of countries health expenditure (WHO, 2010c).  
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Within the context of Palestine, in 2014, the Palestinian Central Bureau of Statistics (PCBS) 
(2016) demonstrated that the Palestinian National Authority (PNA) spent about 11% of the 
Gross Domestic Product (GDP) on health. Low level of physicians' compliance to the 
Essential Drug List (EDL) will affect directly resource allocation and utilization through 
overuse of some items and overstock of others leading to interruption of these services. Few 
studies are conducted internationally to assess the compliance of physicians with EDL.  
 
 Physician‘s compliance to EDL is an indicator for maximization of the use of current 
resources and decreasing waste (Khan and Ara, 2011). Physician‘s compliance with EDL 
would save resources and improve the efficiency and effectiveness of drugs use.  
1.3. Justification of the study 
During the last five years, the General Directorate of Hospitals in the GG has received many 
complaint letters from different hospitals concerning drug use. Some of the complaints were 
justified by shortage of EDL drugs despite their availability in Central Drug Stores. Others 
included requests for new drugs that are out of EDL despite the presence of alternative drugs 
in EDL. The magnitude of these complaints is not well known, although they come from 
different hospitals and different specialties. 
 The General Directorate of Hospitals also noticed through patient complaining letters that 
some prescribed drugs are absent in hospitals as well as in private market. In the absence of 
commitment to prescribe drugs included in EDL, physicians write two different prescriptions 
to the same patient; the first is directed to the hospital pharmacy to dispense EDL drugs, the 
second one containing NEDL drugs to purchase it from the private market. Writing the 
medications in two different prescriptions makes it impossible for pharmacists to practice 
clinical pharmaceutical interventions about the dose, indication, drug interactions, making it 
more susceptible for presence of drug interactions. Some of these drug interactions may be 
significantly harmful. Harmful interactions may cause irreversible effects including organ 
damage as renal or hepatic failure. Also prescribing NEDL drugs pushes the patients to buy 
drugs out of their pocket, hence increasing the financial burden on the patients and their 
families and decreasing financial protection and satisfaction with health care services. 
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Moreover, poor patients cannot buy medicine out of their pocket which eventually leads to the 
deterioration in their health status. 
To the best of the researcher‘s knowledge, no previous research studies have been carried out 
concerning physicians' compliance with EDL in governmental hospitals in GG. Thus, this 
study will provide signals that could help identify best ways to promote rational use of drugs 
through assessing physician‘s compliance with EDL and identify influencing factors. 
Improving physician‘s compliance with EDL would improve the efficiency of available drugs, 
maximize the utilization of available drugs, and prevent wastage of the limited resources. 
1.4. Aim of the Study 
The study aims to assess physicians‘ compliance with EDL at governmental hospitals in the 
GG. The study will propose recommendation to improve physicians‘ prescribing practice. 
1.5. Objectives 
More specially, the study aims to address the following objectives: 
1. Assess the level of physicians‘ compliance with and commitment to EDL 
2. Examine physicians‘ current level of knowledge, attitude and practice concerning EDL at 
governmental hospitals 
3. Explore factors that might hinder physicians‘ compliance with EDL 
4. Propose recommendations that could improve physicians compliance with EDL 
1.6. Research questions   
This study will answer the following questions: 
1. Are physicians aware of the concept of EDL? 
2. Have physicians participated in updating EDL? 
3. To what degree physicians comply with EDL at governmental Hospitals in the GG? 
4. What are the prescribing trends of physicians concerning trade vs scientific names, 
and language of writing?  
5. What are the main factors affecting physicians‘ compliance with EDL? 
6. Does the MoH implement effective EDL orientation programs for the medical staff? 
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7. Do hospital pharmacists play their roles in improving physician compliance with 
EDL? 
8. Do we have variations in physician‘s compliance among different hospitals and 
different medical forms? 
9. Were the MoH management efforts enough in this field?  
1.7. Geographic Context  
The State of Palestine (Annex 1) is located in the west of Asia; it lies between longitudes 33' 
15'' and 29' 30''; and between latitudes 35' 40'' and 34' 15''. The entire area of Palestine is about 
27,009 Km
2
, stretching from Ras Al-Nakoura in the north to Ommerreshrash in the south. 
Palestine is bordered by Lebanon in the north with a border length of 79 Km; Syria with 
border length of 70 Km, and Jordan with a border length of 360 Km from the east. To the 
south, Palestine is bordered by Egypt with a total length of 240 Km border. Mediterranean Sea 
limits Palestine from the west with a coast length of 224 Km. Palestine also overlooks the Gulf 
of Aqaba with a coast length of 10.5 Km (Dabbagh, 1997). Nowadays, PNA is limited to two 
geographically separated areas, Gaza governorates (also called southern governorates, Gaza 
strip, GS), and West Bank governorates (also called northern governorates, WB), with a total 
area of 6020 km
2
 which represents 22% of historical state of Palestine (PCBS, 2013a). 
GG (Annex 2) is a small narrow band of land; it is 45 km long and 6-12 km wide, located in 
the southern area of the historical state of  Palestine on the coast of Mediterranean with an area 
of 365 km
2 
 (Dabbagh, 1997). It is divided into five governorates: North Gaza, Gaza, Mid 
Zone, Khan Younis, and Rafah (PCBS, 2013a). The total land boundaries of GG are 62 Km: 
Egypt 11 Km, and Israel 51 Km (PCBS, 2014). 
1.8. Palestinian health care system   
 The Palestinian health care system is a complex one; it covers wide range of Primary 
Health Care (PHC), secondary health care, and tertiary health care. There are four main health 
care providers: MoH, United Nations Relief and Works Agency for Palestine Refugees in the 
Near East (UNRWA), Non-Governmental health Organizations (NGOs), and private for-profit 
health service providers (MoH, 2014). MoH is the main health care provider in PNA; it 
provides primary, secondary, and tertiary health care services. It purchases advanced medical 
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services through referring patients to the neighboring countries and other private and NGOs 
health care facilities (MoH, 2014). UNRWA provides basic primary health care services and 
some secondary care services to the Palestinian refugees (MoH, 2014).    
1.9. Demography context 
According to PCBS (2015), the total estimated population of the PNA at mid-2015 was about 
4.68 million; 2.38 million males and 2.3 million females. The total estimated population of the 
GG was 1.82 million. Data revealed that the population of the PNA is a young population; as 
the percentage of individuals aged 0 to 14 constituted 39.4% of the total population at mid-
2015, of which 37.2% are in WB and 43.0% in GG. The elderly population aged 65 years and 
over constituted 2.9% of the total population of which 3.2% are in WB and 2.4% in GG at 
mid-2015. Population density is generally high in GG; reaching 4,986 persons/km
2
, as per 
PCBS (2015). The average household size in PNA was 5.2 in 2014: 4.9 in WB and 5.7 in GG. 
The natural rate of increase of the population was 2.9% in 2015; 2.6% in WB and 3.4% in GG 
(PCBS, 2015).  
In 2012, Palestinian refugees constituted 42.1% of the total population: 27.0% in WB and 67.0 
% in GG. In 2015, life expectancy at birth in PNA was 73.5: 72 years for males and 75 years 
for females (PCBS, 2015). 
1.10. Socio-Economic Context  
The ongoing blockade, current occupation, frequent wars have weakened the Palestinian 
economy to unprecedented level. In the year 2012, the estimated per capita GDP was 1679.3$: 
2093.3$ in WB and 1074.5$ in GG (PCBS, 2013b).  
Labor force participation rate in 2015 was 45.6%, distributed as 71.7% for males and 18.8% 
for females (PCBS, 2015). In 2015, Out of the total rate of employment: full employment rate 
was 70.8%, underemployment rate was 3.6%, and unemployment rate was 25.6% (PCBS, 
2015). According to the United Nations Office for the Coordination of Humanitarian Affairs 
(OCHA,2014), the current poverty and unemployment rates are very high; In GG, 
unemployment rate has increased dramatically since mid-2013, following halt of the illegal 
tunnel trade with Egypt, soaring from 28% in the third quarter of 2013 to 45% in the second 
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quarter of 2014; almost 70% of the youth aged 20-24 were unemployed in GG in the second 
quarter of 2014 and further deterioration is highly expected (OCHA, 2014).  
The total diffusion rate of poverty among Palestinian individuals was 25.8% in 2011: 17.8% in 
the WB and 38.8% in the GG. In 2014, the poverty rate in the GG has increased to 39% 
(World Bank, 2014). In 2014, the literacy rate was 96.9% in the GG (98.4% for males versus 
95.3% for females) (PCBS, 2015). 
1.11. Political context of GG 
After the beginning of Al-Aqsa intifada (2000), Israeli siege and closure of crossings was 
imposed on the GG. The Israeli authorities implemented a collective punishment to all 
Palestinians in the GG by tightening the siege more intensively after the Palestinian legislative 
elections in 2006 and the election of Hamas Islamic movement. Intensity of the sieges and 
continuous blockade of borders were dramatically increased after the political rift in 2007. 
Israel's punitive closure of the GG, particularly the near-total blocking of exports, continued to 
have severe consequences on the Palestinian population.  The allowed imports to GG 
amounted to less than half of the 2006 pre-closure levels (Human Rights Watch, 2014). In 
2013, deterioration of the health status has increased due to bad economic situation after the 
closure of the illegal tunnels with Egypt, which was considered in certain period of time as a 
sole source of all goods needed for GG. The MoH became hardly able to provide all 
operational needs of the health services including drugs, medical disposables, medical 
equipment, lab materials, and others. Additionally, services are frequently interrupted by 
electricity blackouts and insufficient supplies of drugs and disposables and limited training 
opportunities for medical staff. This further threatens the health of the population, which is 
already at increasing risk (UNRWA, 2014; OCHA, 2014). Following the establishment of the 
reconciliation government, there is a void in local leadership at ministerial levels and 
insufficient cash flow causing an imminent threat of a breakdown in key public health 
services. This comes on top of an already severely strained situation caused by ten years of 
Israeli siege on GG (UNRWA, 2014).  
 
Not only the political conflict led to deterioration in the health status in the GG, but also 
frequent and repeated Israeli wars and attacks, where GG were exposed to three major and 
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devastating wars in the last 7 years: Al Forqan war 2008, Hejarat Al Sejjeel war 2012, and Al 
Asf Al Maakool war 2014. As a result of the last Israeli 51days war on the GG in 2014, 
several health facilities had been closed throughout the hostilities. Some of them have been re-
opened while others have not (OCHA, 2014).  In GG, 50 PHCs and 17 hospitals were either 
partially or totally damaged (OCHA, 2014). During the last war, some of 485,000 people – 
28% of GG population – were internally displaced (OCHA, 2014).  
1.12. Palestinian Ministry of Health 
After the Oslo Accords (1994) between the Israeli government and Palestinian Liberation 
Organization (PLO), PNA was established on the GG, in addition to Jericho city, which was 
known as the first phase of the Convention: Gaza-Jericho phase. Health care provision, 
supervision, regulation, licensure, and control of all health services were transferred to the 
Palestinian MoH in 1994 (Abed, 2007). Despite aid assistance by international donors, health 
sector has been suffering from chronic financial crises due to increased demand on health 
services which resulted from ongoing increase in the population growth, frequent wars, and 
political rift between GG and WB (Palestinian Non Governmental Organizations Network, 
2009; Abed, 2007). 
 
 The MoH is composed mainly of main general directorates including hospitals, primary 
health care, pharmacy, human resources development, health finance and management, 
inspection and control, international cooperation, engineering and maintenance, and legal 
affairs. It also includes many units such as insurance, nurses, laboratories and blood banks, 
referral abroad, rehabilitation, health information center, Information and technology, strategic 
planning, psychiatric health, emergency services, and accreditation and licensing. Hospitals 
are a key component for effective performance of the Palestinian health care system (MoH, 
2013).  
1.13. Health indicators 
In 2015, the crude birth rate was 31.9 per 1000 population (29 in WB, and 36.3 in GG) and the 
crude death rate was 3.6 per 1000 population (3.7 in WB, and 3.4 in GG) (PCBS, 2015). 
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The overall number of hospital beds in PNA is 5,414 beds distributed over 79 hospitals; 49 are 
in WB with 3,163 beds hospital beds, 30 hospitals with 2,251 beds in GG (MoH, 2013). In the 
year 2012, Bed occupancy rate was 82.7% with an average of 2.4 days residency in hospital 
(PCBS, 2013b). 
1.14. Governmental hospitals in GG:  
In GG, there are 12 governmental hospitals, the total number of governmental hospital beds in 
2015 was 1639 for inpatients. Bed occupancy rate was 84.43% with an average of 3.89 days 
residency in hospital (MoH, 2015). 
1.15. Pharmacy and Therapeutics committee 
According to WHO (2003), Pharmacy and Therapeutics committee (P & T committee), also 
called Drug and Therapeutics Committee (DTC) in some countries is considered as an integral 
element in the development of rational guidelines, following Evidence-based medicine 
approaches, aims for implementation of appropriate medicine policies to ensure that patients 
are provided with the best possible care at a high quality and a cost effective manner through 
selecting what medicines will be available, at what cost, and how they will be used. P & T 
committee became a main bone for the exchange of ideas and knowledge among physicians, 
clinical pharmacologists and pharmacists (Hoffmann, 2013). According to the American 
Society of Health System Pharmacists, P&T committee should serve in an evaluative, 
educational, and advisory capacity to the medical staff as well as in organizational 
administration in all matters that pertain to the use of medications (Tyler et al., 2008)  
In the Palestinian context, P & T committee is considered as advisory group composed of 
experts. It has two levels: a central committee concerned with national drug decisions between 
alternatives and composed mainly of physicians and pharmacists of different specialties, while 
hospital level committee composed primarily of physicians, pharmacists, and may include 
nurse and lab technicians. In hospitals, P & T committee serves as the communication link 
between the medical staff and the pharmacy department. Its primary goal is cost containment, 
and priority setting in case of drug shortage. 
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1.16. Operational definitions of terms 
Essential Drug List: is the list of drugs that satisfy the priority health care needs of the 
population (WHO, 2013b). 
 
Drugs: Any material acknowledged registered in the pharmacopeia, also any material which is 
used to diagnose, or cure, or treat or to help any human or animal disease, or any non-food 
material intended to impact the human body or an animal with respect to environment or vital 
functions of any of them (Public Health Law, 2004). 
 
Key drugs: A short list of specific drugs (less than 15) those are essential to treat common 
health problems in specific countries (WHO, 1993). 
 
Physicians Compliance: the extent to which physician‘s behavior matches the 
recommendations 
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Chapter (2) 
 
   Literature review 
This Chapter starts by presenting the conceptual framework guiding this study; then, it 
highlights the essential drugs concept, selection criteria, process and update, rational drug use 
and ways to promote the rational drug use and causes of irrational drug use.  Finally, it 
reviews the history and current status of the Palestinian EDL. 
2.1 Conceptual framework 
The guiding conceptual framework in the study is shown in Figure (2.1).  Two major groups 
of factors were included in the research framework: physicians and health facility related 
factors. Another third group of factors related to the MoH high level management. All these 
factors are relevant and affect the compliance of physicians working in MoH hospitals. 
 
The first major group of factors is related to physician‘s characteristics. This group is divided 
into five sub divisions.  Firstly, socioeconomic characters of the study participants such as 
marital status, gender, age, and residency. Secondly, work related characteristics of the study 
participants such as specialty, place of work, academic qualifications, years of work 
experience, and managerial position. Thirdly, the study participants knowledge about the 
essential drugs list contents, EDL concept, EDL selection criteria, and benefits. Fourthly, the 
study participants attitude towards the essential drugs list, EDL concept, EDL selection 
criteria, and benefits. Fifthly, other factors including private work and medical representatives 
of pharmaceutical companies influence. 
The second major group of factors is related to the health facility characteristic. This group is 
divided into four sub divisions. Firstly, activities related to the pharmacy and therapeutics 
committee in the hospital. Secondly, activities related to the hospital Monitoring and 
Evaluation system and its feedback. Thirdly, the availability of EDL drugs in the study 
settings. Fourthly, the hospital pharmacy related activities. 
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The third major group of factors is related to MoH high level management. This group is 
divided into three sub divisions. Firstly, issues related to guidelines, policies, and procedures 
establishment and dissemination efforts. Secondly, MoH training programs issues. Thirdly, 
actions related to the MoH Audit system activities. 
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Figure (2.1): Conceptual framework 
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2.1.1 Physician’s characteristics  
Physician‘s characteristic includes socioeconomic characteristics, years of work experience, 
work attitude, and knowledge. Socioeconomic characteristics includes: age, gender, place of 
permanent residency, place of work, managerial positions gained during his work, and type of 
medical specialty.  
In relation to the physician‘s knowledge and attitude, according to WHO guidelines, the 
medical staff should have adequate knowledge and training in the health care service they 
provide. The medical staff attitude towards prescribing drugs from the EDL will affect their 
compliance with it and the service they provide. Compliance with EDL needs a specialized 
medical staff who believes that EDL will improve the services more than other drugs (WHO, 
2002a). 
2.1.2 Health facility related factors 
 Health facility related factors will include the availability of policy and procedures, guidelines 
and protocols, Pharmacy and Therapeutic committee (P & T committee), monitoring system, 
drug availability system, training system, feedback system,  and hospital pharmacy influence. 
Compliance is established effectively and efficiently in the presence of policies and guidelines 
(WHO, 2003). Pharmacy and therapeutic committee (also known as Drug and therapeutic 
committee; P & T committee) have brought pharmacists into closer formal working 
relationships with other hospital medical specialists to devise hospital policies. Its main 
objective is to ensure the efficiency and quality of hospital services through optimal use of 
drugs (MoH, 2008; WHO, 2003).  
Hospital pharmacy influence: Pharmacists are the main professionals dealing with drugs; they 
are considered as the sole drugs experts at the hospitals (MoH, 2013).  Pharmacists have a 
strong influence on physicians compliance through direct and continuous communication with 
physicians and induction of compliance with EDL. Expanding the role of hospital pharmacist 
has improved the medication use process in a high-risk population through improvements in 
medication overuse, medication underuse, dosing, medication reconciliation, patient 
education, and health care provider education (Reilly et al., 2012). 
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The availability of drugs in health care facility is so crucial that no health care services can be 
provided without such availability. It represents one of the main building blocks of a sound 
health care system (WHO, 2010a). 
2.1.3 MoH management 
MoH management has an important role in increasing the physician‘s compliance with the 
EDL through exercising efforts related to establishment and updating of the MoH EDL, 
dissemination of knowledge related to the EDL as well as printing copies of the list, 
Monitoring and evaluation system, and drug supply efforts.   
2.2   Literature review 
2.2.1 Essential Drug List Concept  
In 1977, the first WHO`s EDL was drafted; the concept was to promote rational use of drugs 
(RUD). Selection of essential drugs is linked to the approved treatment guidelines, it has a 
significant effect on promoting health professionals and consumers RUD and increases the 
access to health care services generally (WHO, 2002b). EDL is used as a powerful tool for 
promoting health equity in order to address the gap in access to drugs between citizens of high 
income countries and those of low income countries (Millar et al., 2011). In establishing a 
local country EDL, the WHO`s EDL represents an important key element in which it serves as 
a model for public supply and reimbursement (Millar et al., 2011).  
On the other hand,  some argue that, following the EDL list principle delays  the inclusion of 
new medicines, harm the research and development activities since sponsors won′t be afraid 
about new medicine's market potential (Bansal & Purohit, 2013).  Moreover, following the 
EDL list principle has many challenges; the most common challenges are: to regularly update 
the EDL in the light of new therapeutic options; changing therapeutic needs according to 
epidemiological profile of the population; the need to ensure drug quality; the need for 
emerging diseases drugs and drugs for coping with changing resistance patterns (Bansal & 
Purohit, 2013). 
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2.2.2 Selection criteria, process and update of EDL 
  Essential drugs selection process is critical, and it is so important that the process 
should be consultative and transparent. Selection criteria should be explicit and be linked to 
evidence-based standard clinical guidelines (Kar et al., 2010; WHO, 2002b). Those clinical 
guidelines should be agreed on and accepted by the health care professionals and the system as 
a reference for treatment. Both of the treatment guidelines and EDL are regularly reviewed 
and updated at least every two year; their use and impact should be monitored (Kar et al., 
2010; WHO, 2002b).  
The selection of Essential Drugs represents one of the core principles of a national drug policy 
(WHO, 2002b). Countries apply the EDL concept to achieve the best possible health outcomes 
within available resources (WHO, 2002b). 
The selection of Essential Drugs is a two-step process, the first of which is market approval of 
a pharmaceutical product and the second is an evaluation process based on comparison among 
various drug products on considerations of effectiveness and cost (WHO, 2002b). 
 
The WHO expert committee (2002) recommended and used the following criteria for selection 
and use of Essential Drugs: (1) only drugs for which sound and adequate evidence of efficacy 
and safety in a variety of settings is available should be selected; (2) relative cost-effectiveness 
is a major consideration for choosing drugs within the same therapeutic category. In 
comparisons between drugs, the total cost of the treatment – not only the unit cost of the drugs 
– must be considered, and be compared with its efficacy; (3) in some cases, the choice may 
also be influenced by other factors such as pharmacokinetic properties or by local 
considerations such as the availability of facilities for manufacture or storage; (4) each drug 
selected must be available in a form in which adequate quality, including bioavailability, can 
be ensured; its stability under the anticipated conditions of storage and use must be 
determined; (5) most essential drugs should be formulated as single compounds. Fixed dose 
combination products are selected only when the combination has a proven advantage in 
therapeutic effect, safety, and adherence or in decreasing the emergence of drug resistance. 
The WHO essential medicines policies are associated with improved quality use of medicine, 
particularly in low-income countries (Holloway & Henry, 2014). 
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2.2.3 Rational Use of Drug (RUD)  
The selection of Essential Drugs is only one step towards the improvement of the quality of 
health care services; selection needs to be followed by an appropriate use. Each individual 
should receive the right drug, in an adequate dose for an adequate duration, with an 
appropriate information and follow-up treatment, and at an affordable cost (Kar et al., 2010). 
RUD (also called rational use of medicine RUM) is defined as ―Patients receive drugs 
appropriate to their clinical needs, in doses that meet their own individual requirements, for an 
adequate period of time, and at the lowest cost to them and their community‖ (WHO, 2002a).  
According to WHO, not only the irrational (also called inappropriate)  use of drugs for chronic 
and infectious diseases is widespread, costly and extremely harmful to both the individual and 
populations as a whole, but also it increases the incidence of adverse drug events and 
resistance. Moreover, WHO classified the common types of irrational drug use to be: (1) the 
use of too many drugs per patient (poly-pharmacy prescriptions); (2) inappropriate use of 
antimicrobials, often in inadequate dosage, for non-bacterial infections; (3) over-use of 
injectable when oral formulations would be more appropriate; (4) failure to prescribe in 
accordance with standard clinical treatment guidelines (STGs); (5) inappropriate self-
medication, often of prescription only medicines (WHO, 2002a). 
Causes of irrational use of drugs include lack of knowledge, lack of skills or independent 
information, unrestricted availability of drugs, overwork of health personnel, inappropriate 
promotion of drugs and profit motives from medical and selling representatives of private drug 
companies (WHO, 2002a). 
2.2.4 Promotion of RUD  
  Promoting RUD will result in improved quality, increased accessibility, and better 
quality of life for the community (Khan & Ara, 2011). Moreover, rational prescribers should 
attempt to maximize clinical effectiveness, minimize harms, avoid wasting limited healthcare 
resources, and respect patient's choice (Khan & Ara, 2011). Due to limited resources of 
healthcare systems and the rapidly increasing cost of drugs, prescribers are forced to consider 
cost effectiveness as an important factor in drug selection; selecting a generic rather than a 
branded drug from the same therapeutic class represents an example of cost effective 
prescribing (Khan & Ara, 2011). 
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The WHO (2002) recommended twelve useful and effective core interventions to promote 
RUD. However, when these activities are being implemented, care is necessary to ensure 
success.  These twelve core interventions include: (1) a mandated multi-disciplinary national 
body to coordinate drug use policies; (2) standard clinical treatment guidelines (STGs); (3) 
EDL based on treatments of choice; (4) drug and therapeutic committees in districts and 
hospitals (also called Pharmacy and Therapeutic committees, P&T committee); (5) problem-
based pharmacotherapy training in undergraduate curricula; (6) continuing in-service medical 
education as a licensure requirement; (7) supervision, audit and feedback; (8) independent 
information on drugs; (9) public education about drugs; (10) avoidance of perverse financial 
incentives; (11) appropriate and enforced regulation; and (12) sufficient government 
expenditure to ensure availability of drugs and staff. 
Addressing the irrational prescribing, dispensing and patient use of drugs should be regularly 
monitored in terms of: (1) types of irrational use; (2) amount of irrational use; and (3) reasons 
why drugs are used irrationally (WHO, 2002a). 
2.2.5 Palestinian EDL 
In the year 2000, MoH adopted its first EDL. A national committee was established of highly 
qualified members of all medical specialties including physicians, pharmacists, nurses, public 
health experts, financing experts. The committee included health services representative of the 
MoH, NGOs, private sector, educational institutions, military medical services, and 
international organizations working in the PNA. It also considered the membership of both 
GG as well as WB. The process was guided by the WHO recommendations for selection and 
update of EDL. As a consequence, MoH established the Palestinian National Drug Formulary 
(PNF) in the year 2002 which is considered as the guiding formulary for the use of essential 
drugs for all medical staff working at MoH facilities.  PNF was printed as a Note book and 
disseminated; training courses were implemented among the majority of governmental health 
care staff during the period from 2002 to 2004. Later to this date, EDL was updated several 
times; the last of which was in 2013.  
The total number of updated Palestinian EDL items is 480 which are categorized in the PNF 
(2013) into twenty nine categories: (1) anesthetics; (2) analgesics, antipyretics, non-steroidal 
anti-inflammatory; (3) antiallergics and medicines used in anaphylaxis; (4) antidotes and other 
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substances used in poisonings; (5) anticonvulsants/antiepileptics; (6) anti-infective medicines; 
(7) antimigraine medicines; (8) antineoplastic, immunosuppressives and medicines used in 
palliative care; (9) antiparkinsonism medicines; (10) medicines affecting the blood; (11) blood 
products and plasma substitutes; (12) cardiovascular medicines; (13) dermatological 
medicines (topical); (14) diagnostic agents; (15) disinfectants and antiseptics; (16) diuretics; 
(17) gastrointestinal medicines; (18) hormones, other endocrine medicines and contraceptives; 
(19) immunologicals; (20) muscle relaxants (peripherally-acting) and cholinesterase inhibitors; 
(21) ophthalmological preparations; (22) oxytocics and antioxytocics; (23) dialysis solution; 
(24) medicines for mental and behavioral disorders; (25) medicines acting on the respiratory 
tract; (26) solutions correcting water, electrolyte and acid –base; (27) vitamins, minerals and 
other nutritional supplements; (28) ear, nose and throat; (29) specific medicines for neonatal 
care. 
 
PNF (2013) also included more 10 items categorized as complementary drugs. Currently, in 
the study settings, the total number of drugs that are dealt with is 432 drugs: 350 drug items in 
Al-Shifa Medical complex, 301 drug items in Nasser Medical complex, 359 drug items in 
European Gaza Hospital, 272 drug items in Al-Aqsa Martyrs hospital, and183 drug items in 
Kamal Odwan hospital (MoH, 2013). 
2.2.6   Factors affecting physicians’ compliance with EDL 
2.2.6.1  Physicians’ knowledge about EDL 
According to a Dutch study conducted by Karbach and Colleagues (2011), 40% of the 
physicians know the guidelines adequately; however, the study concluded that physicians‘ 
knowledge of guidelines does not in itself lead to better guideline implementation. Moreover, 
Ossoff and Thomason (2011) found that there is no one compliance program model to fit 
every organization, so there is no one educational model that could fit every organization. 
There are key factors to consider when determining how to approach an educational program 
for any organization. 
According to Oba and Collogues (2006), three factors were identified as being significantly 
associated with physician compliance status: (1) prior participation in clinical trials; (2) 
physician opinion that the support system for case registration and follow-up was well 
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organized; and (3) number of patients treated. Another study conducted by Gustafsson and 
Colleagues (2011), Swedish researchers, revealed that no comprehensive model exists for 
selecting and communicating essential drug recommendations to all physicians to enhance 
adherence and there is a great need for local adaptation of these programs to be more effective. 
Gustafsson study also showed that adherence to the EDL was 77% by substance in 2009. A 
French study conducted by Sellier and Colleagues (2009) found that adherence to 
recommendations with an infectious disease specialist for inpatients was as high as 88% for 
antimicrobial therapy and was associated with a higher prevalence of early clinical 
improvement and a shorter median length of hospital stay. 
With regard to demographic characteristic of physicians, Sherman (2011) found that no 
significant demographic differences were reported between different American physician 
groups, including age, sex, and race, and concluded that Physician-specific factors have no 
impact on medication prescribing compliance with treatment and clinical outcomes. 
Within the Palestinian context, Fattouh and Abu Hamad (2010) studied the physicians' 
compliance with the Palestinian EDL at the governmental PHC centers in GG. The study 
showed that, the vast majority of the study participants (97.2%) were not involved in the 
establishment of the EDL, 67.4% of the respondents reported currently using the EDL and 
51.2% of the respondents faced many problems in using the EDL.  More importantly, the 
study showed that the percentage of drugs prescribed from the EDL was 97.85%, the 
percentage of drugs prescribed by generic names was 5.47%, the availability of a copy of EDL 
at the surveyed clinics was 28.3% and the availability of key drugs was 82.6% .The majority 
of the study participants (79.4%) had a copy of the standard treatment guidelines, 70.1% of the 
study participants reported having copy of EDL, most of the study participants (94.3%) were 
knowledgeable about the essential drugs concept, and around two thirds (65.5%) of the study 
participants did not attend any training courses on EDL. Moreover, Fattouh and Abuhamad 
(2010) found that, only 25.9% of the study participants reported having an evaluation for their 
prescribing practice at their facilities, while 56.6% of the study participants did not receive any 
feedback. (Fattouh & Abu Hamad, 2010). 
 A more recent study was conducted to assess physicians‘ exposure and attitudes towards the 
marketing practices of pharmaceutical companies in GG (Ammar, 2015) in which the 
researcher found that MoH hospitals‘ physicians are highly exposed to the marketing practices 
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of the pharmaceutical companies, as 95.1% of them are exposed to 10 marketing practices 
used by pharmaceutical companies. Moreover, Ammar (2015) found that MoH hospitals‘ 
physicians have positive attitude towards the marketing practices and the information provided 
by pharmaceutical companies through marketing practices, and they consider such information 
important and credible. Ammar also found that MoH hospitals‘ physicians are aware of the 
regulation of the marketing practices in general (Ammar, 2015). 
De Ferrari and Colleagues (2014), who studied the attitudes and relationship between 
physicians and the pharmaceutical industry in a public general hospital in Peru, found that 
94.5% of attending physicians reported ongoing encounters with pharmaceutical 
representatives. Ammar (2015) mentioned that the Palestinian status is suffering from poor 
regulatory process for pharmaceutical companies. Promotional materials may not always be 
compliant with current evidence-based and ethical standards (Olivier et al., 2015) 
Physician’s knowledge: 
According to Mariam and Colleagues (2015), a study conducted in a Southern Ethiopian 
hospital, 72.2% of physicians were aware of the existence of the EDL. While, Mulwa and 
Colleagues (2015) found that 80% of the study Participants at the Alexandrian primary health 
care centers informed that they have copies of EDL. According to Gupta and Colleagues 
(2015), a study conducted at tertiary care teaching hospital in South India, 75.3% of 
physicians agreed that generic drugs are as safe as innovator drugs, 64.4% of physicians agree 
that generic drugs are as effective as brand-name drugs, 63% of physicians said that they 
prescribe generic drugs, and 89% of physicians agreed that that there should be training 
programs to increase the awareness regarding generic drugs among doctors. According to 
Hettihawa and Jayarathna (2010), who studied the Knowledge in core Policies of EDL among 
medical practitioners in comparison with medical students in Sri Lanka, only 54% of the study 
participants have true Knowledge on core policies of EDL, physicians level of knowledge on 
time frame for revision of EDL was very low (17%), the level of knowledge of physicians on 
contents of EDL was 63%, the knowledge of physicians about the criteria for selection of EDL 
was 83%. According to Khan and Colleagues (2011), who studied the rational prescribing 
among medical practitioners in Bangladesh, 58.6% of the physicians reported that they did not 
have any clinical practice guidelines in their clinics. 
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Physicians practice: 
According to Mariam and Colleagues (2015), a study conducted in a Southern Ethiopian 
hospital, the majority of the prescriptions (67.7%) contained two to three drugs, the average 
number of drugs was 2.3 drugs per prescription, drugs prescribed in Generic names constituted 
96.8% of the prescriptions, and 88.7% of the prescribed drugs were from the Ethiopian EDL 
(Mariam et al., 2015). According to Chedi and Colleagues (2015), a study conducted in 
Northern Nigerian provinces, the mean number of drugs prescribed was 2.97 drugs per 
prescription in hospitals, while it was 3.62 drugs per prescription in the primary health care 
facilities. Prescribing drugs by Generic names constituted 61% of the hospital prescriptions, 
while it was 55% of the primary health care facilities prescriptions. The percentage of drugs 
prescribed from the Nigerian EDL was 89.8% among the primary health care facilities 
compared to 91.8% in the hospitals (Chedi et al., 2015). According to Ingle and Colleagues 
(2015), an Indian study, the average number of drugs prescribed was 3.5 per prescription. The 
overall percentage of drugs prescribed from India‘s EDL was 51.05%. 
According to Prasad and Colleagues (2015), another study conducted in India at a secondary 
care referral hospital, the average number of drugs per prescription was 2.7 drugs, 42.9% of 
the prescribed drugs were in Generic names, and 95.6% of the prescribed drugs were from the 
India EDL (Prasad et al., 2015). According to Goel and Colleagues (2015), an Indian study 
conducted in tertiary care teaching hospital in Ghaziabad, only 38.83% of the drugs were 
prescribed by Generic names, and 41% of the prescribed drugs were from the EDL. According 
to Ndukwe (2013), a study conducted in Nigerian teaching hospital, the average number of 
drugs per prescription was 3 drugs, 70.2% of the prescribed drugs were by Generic names, and 
the drugs prescribed from the hospital formulary constituted 88% of the total number of 
prescribed drugs. According to Afriyie and Colleagues (2014), a study conducted in Ghanian 
military hospital, the average number of drugs per prescription was 3.7 drugs, 62.6% of the 
prescribed drugs were by Generic names, and the drugs prescribed from the hospital formulary 
constituted 53.6% of the total number of prescribed drugs. 
 According to Adibi and Colleagues (2012), an Indian study conducted in tertiary care 
teaching hospital, the average number of drugs per prescription was 4.22 drugs, only 3.8% of 
the prescribed drugs were in Generic names, and 53.3% of the prescribed drugs were from the 
India EDL. According to Mulwa and Colleagues (2015), a study conducted in Kenyan referral 
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hospital, the mean number of prescribed drugs was 2.48 drugs per the in-patient prescription, 
while it was 2.7 drugs per the out-patient prescription. Prescribing drugs by Generic names 
constituted 45% of the in-patient prescriptions, while it was 47.6% of the out-patient 
prescriptions. The percentage of drugs prescribed from the EDL was 90.6% among the in-
patient prescriptions compared to 82.8% among the out-patient prescriptions. According to 
Akl and Colleagues (2014), an Egyptian study conducted among the primary health care 
centers at Alexandria province, the average number of drugs per prescription was 2.5 drugs, 
95.4% of the drugs were prescribed by Generic names, and 95.4% of the drugs were 
prescribed from the Egyptian EDL. According to El-Mahalli (2012), a Saudi Arabian study 
conducted among the primary health care centers of the eastern province, the average number 
of drugs per prescription was 2.4 drugs, 61.2% of the drugs were prescribed by Generic 
names, and 99.2% of the drugs were prescribed from the Saudi Arabia EDL. 
Drug information sources 
According to Zeidan (2015), the majority of the study participants (65%) used internet for 
searching medical information through PubMed as a favored Medline search engine, while 
García and Colleagues (2011) found that the internet sources were considered useful by nearly 
two thirds (62%) of participants. Kamal and Colleagues (2014), showed that physicians 
obtained drug related information from many sources; the most common are: drug information 
sheets (drug package leaflet) (25.6%), text books (20.4%), scientific journals (8.5%), while 
only 9% of the study participants obtained their information from medical representatives of 
drug companies. Thriemer and Colleagues (2013) found that the sources of information for the 
physicians who participated in the study were: pharmaceutical companies (76.9%), treatment 
guidelines (62.8%), the internet (51.3%), and university courses (37.2%). Kargar and 
Colleagues (2016) found that the main source of physician information was the colleagues. 
Quet and Colleagues (2015) revealed that 86.5% of the doctors obtained information from 
national guidelines, 85.1% of the doctors obtained information from peer advice, 82.6% of the 
doctors obtained information from older colleagues, 76.9% of the doctors obtained 
information from representatives of pharmaceutical drug companies, while the internet as a 
source of information represented 73.9% for physicians. 
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Educational intervention 
Imparting the knowledge and awareness among the health care professionals by means of  
learning initiatives and continuous educational intervention would bring updated knowledge 
and attitude of practice for drug safety (Kargar et al., 2016; Ingle et al., 2015; Asadpour et al., 
2015; Kamal et al., 2014; Palaian et al., 2011; Rajesh et al., 2011). These continuing education 
programs give a chance to health care field specialists to acquire new knowledge, skills and 
competences and to refresh the existing professional skills (Puķīte, 2015). Moreover, to 
increase physicians compliance with EDL, these educational interventions have to include 
information about local EDL concepts and benefits, the importance of renewing public 
confidence in the quality of locally available EDL, and the revision and dissemination of local 
guidelines (García et al., 2011). Delivery of these training courses should be assisted by local 
‗experts‘ who are able to customize course content to meet local requirements and the 
requirements of different staff groups (Brand, 2015). Frequent appraisal of the EDL concepts 
and amendment can make the EDL concept more familiar to physicians (Hettihawa & 
Jayarathna, 2010). 
Regarding the presence of feedback system for physician‘s compliance, several studies found 
that an effective feedback should be an integral part of clinical practice of physicians and it 
should be part of a broader quality improvement initiative (Sullivan et al., 2016; Kaye et al., 
2014). Senior leaders and stakeholders of the health care system must be involved in the 
development of the feedback process (Sullivan et al., 2016; Kaye et al., 2014). Those senior 
leaders and stakeholders should be properly trained on how best to give constructive, 
supportive feedback without fear of an antagonistic reaction from the recipient (Kaye et al., 
2014). Feedback is best when it detects problems early; provides information in real time; and 
focuses on goal-oriented behavior (Kaye et al., 2014). Feedback is more readily embraced and 
embedded within the health facility culture when viewed as part of physicians‘ lifelong 
learning (Kaye et al., 2014). Moreover, direct provider feedback on medication prescribing 
errors does not require significant time investment; it can be performed in a non-punitive 
manner; and may decrease the incidence of prescribing errors (Sullivan et al., 2013). On the 
other hand, Jamtvedt and Colleagues (2010), a study conducted to detect the Audit and 
Feedback effects on professional practice of physicians, found that Audit and feedback 
generally leads to small but potentially important improvements in professional practice. The 
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study concluded that the effectiveness of the Audit and feedback system seems to depend on 
baseline performance and how the feedback is provided. According to Hinchcliffe and Wales 
(2010), the quality of pharmacist‘s recommendations to physicians increases when 
pharmacists have more medical information about the patients. Good working relationship 
between the physician and pharmacist is crucial for good impact of pharmacist 
recommendations and acceptance by physicians (Adams et al., 2015; Blenkinsopp et al., 2012; 
Hinchcliffe & Wales, 2010; Holland et al., 2008). Moreover, written recommendations from 
the pharmacists to the physicians, in the absence of other forms of communication, have 
limited effect on physicians compliance; the studies also found that Pharmacist medication 
review of patient files can lead to reduction in inappropriate prescribing behavior of 
physicians; reductions in all prescribed items; and consequently lower treatment costs 
(Blenkinsopp et al., 2012; Hinchcliffe & Wales, 2010). Finally, pharmacist interventions and 
recommendations to physicians are effective when this intervention and recommendation has 
similar components (Holland et al., 2008). 
According to Kenefick and Colleagues (2008), the main barriers to physician guideline 
adherence include: lack of sufficient financial incentives for physicians to change their 
behavior; lack of information technology systems that provide sufficient access to guidelines 
at the point of care; physician culture, beliefs and habits that resulted from failure of providing 
physicians with comparative feedback on their performance; the development of treatment 
guidelines. Moreover, Cabana and Colleagues (1999) mentioned that, barriers to guideline 
adherence include: lack of physician‘s knowledge as the most frequently barrier; low self-
efficacy and negative outcome expectancy beliefs on the part of physicians; patient barriers; 
environmental barriers such as lack of time and insufficient staff support. 
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Chapter (3) 
Methodology 
This chapter illustrates the research methodology of this study. The chapter presents the study 
design, study settings, period of the study, target population, sample size, data collection tools, 
eligibility criteria, and scientific rigor. It also presents the data collection process, response 
rate, data entry and statistical analysis, ethical and administrative considerations, and 
limitations of the study. 
3.1. Study design  
The design of the study is a Cross-sectional. Cross-sectional design is practical, relatively 
simple, cheap, easy, and enables the researcher to meet the study objectives in a short time 
(Martins et al., 2005).  
3.2. Study Settings  
This study was conducted at the five general governmental hospitals in the GG: Al-Shifa 
Medical complex, Nasser Medical complex (Nasser), European Gaza hospital (EGH), Al-Aqsa 
Martyrs hospital, and Kamal Odwan hospital which was moved to and renamed as Al-Rahma 
Indonisi hospital. For detailed information about the study settings, see annexes (3&4).   
3.3. Period of the study 
The study has started after having the university's approval of the proposal and after obtaining 
the ethical approval from Helsinki Committee in Jul 2015. Pilot study was conducted in 
August 2015 then data collection began in October 2015. Data entry and cleaning were 
conducted in March 2016 and finally, data analysis was performed in March 2016. The study 
final report was completed in July 2016. 
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3.4. Target population 
The study population included all physicians working at the five mentioned hospitals who 
practice prescribing drugs; either as in-patient or out-patient departments those satisfy 
inclusion criteria with a total number of 1,272 physicians. 
3.5. Sample size 
Within the context of the study, hospital is considered as a facility. Since the number of health 
facilities is less than 20, a minimum of 600 samples should be collected per facility to conduct 
the study (WHO, 1993). Sample size varies according to the data collection instrument, 
Physicians knowledge and attitude was assessed by using a self-administered questionnaire, 
while physicians practice was triangulated by assessing the data from different sources 
including emergency department reports, in-patient discharge reports, and in-patient 
medication sheet (also known as Cardex). 
3.5.1. Self-administered questionnaire 
 According to MoH, 1272 physicians work- at the study settings: 543 physicians at Al-Shifa 
Medical complex, 250 physicians at Nasser Medical complex, 178 physicians at European 
Gaza Hospital, 189 physicians at Al-Aqsa Martyrs hospital, and 112 physicians at Kamal 
Odwan hospital (MOH, 2013). Sample size was calculated according to the total number of 
physicians working in each hospital. The following parameters were used to calculate the 
sample size:  
• Maximum acceptable percentage points of error 5%  
• Confidence level at 95% 
• Total population (1272).  
 Using a stratified proportionate sampling approach, the total estimated sample size was 300 
physicians: 128 from Al-Shifa, 59 from Nasser, 42 from EGH, 44 from Al-Aqsa, and 27 from 
Kamal Odwan hospital. The sample of the 300 physicians took into account non respondents. 
The questionnaire was used to collect data on physicians‘ knowledge and attitude toward 
EDL. 
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Table (3.1): The total number of physicians working at the study settings and sample size 
calculation 
No Hospital 
Current number of 
physicians 
% of total sample Sample size 
1 Al-Shifa Medical complex 543 43 % 128 
2 Nasser Medical complex 250 20 % 59 
3 European Gaza Hospital 178 14 % 42 
4 Al-Aqsa Martyrs hospital 189 15 % 44 
5 Kamal Odwan hospital 112 9% 27 
Total 1272 100 % 300 
 
3.5.2. Observational checklists:  
3.5.2.1. Emergency department reports: 
From each hospital, a total of 200 reports were randomly selected with a daily average of 20 
reports. Reports not including drugs or not written in a clear handwriting were excluded. In 
total, 1595 reports were reviewed and recorded from all study locations.  
3.5.2.2. In-patient discharge report: 
 From each hospital, a total of 200 reports were randomly selected with a daily average of 20 
reports. Reports not including drugs or not written in a clear handwriting were excluded.  In 
total, 1226 discharge summary reports were reviewed and recorded from all study locations. 
3.5.2.3.  In-patient medication sheets: 
 From each hospital, a total of 200 reports were randomly selected with a daily average of 20 
reports. Sample was taken from the medical records after discharge of patients to ensure that 
all medical management was fully done to the patient. In total, 1098 sheets were reviewed and 
recorded from all study locations. The three checklists were used to collect data on Physicians‘ 
compliance with EDL. 
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3.6. Data collection tools 
Data were collected in two different ways: 
3.6.1. Questionnaire 
Data were collected through well-structured self-administered questionnaire (Annex 5). The 
questionnaire was designed with reference to those concepts mentioned in the conceptual 
framework.  
The questionnaire comprised 80 multiple choice and Likert scale questions related to 
knowledge and attitude of physicians. They were grouped into 10 domains. The first nine 
domains addressed: (i) professional profile; (ii) awareness of EDL concept and process; 
(iii) attitude to EDL; (iv) knowledge and attitude toward standard treatment guidelines; 
(v) knowledge and attitude toward governmental monitoring and audit system; (vi) the 
selection criteria of essential drugs; (vii) attitude toward hospital management, hospital 
pharmacy, and pharmacy & therapeutics committee role and practice; (viii) role of medical 
representatives of pharmaceutical companies; and (ix) socio-demographic questions were 
placed at the end of the questionnaire to avoid influencing physicians` mode  during filling the 
questionnaire and to  decrease rejection due to demographic characteristics. 
Additionally, the questionnaire included two other questions; the first was for drugs suggested 
by participants to be added to the EDL, and an open question at the end of the questionnaire 
asking for reasons that might lead physicians to prescribe NEDL, intended for further probing. 
Questions used to measure the knowledge and practice was designed as multiple choice 
questions consisting of two to six choice answers. Likert scale questions used to measure the 
attitude were based on statements and physicians were asked to indicate the extent to which 
they agree with those statements, on a pre-determined scale (strongly disagree, disagree, 
uncertain, agree, strongly agree). 
Finally, the questionnaire included few continuous variable questions about, years of work 
experience, age, frequency, and duration of pharmaceutical company‘s medical representatives 
visits.   
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3.6.2. Checklist 
Observational checklists were used to collect data from the inpatient discharge summary, 
emergency department presenting report, and inpatient medication sheet. In order to increase 
research findings value and credibility, triangulation for physicians prescribing behavior was 
done by recording three different source forms of prescriptions (Annex 6). The initial 
checklist consisted of the hospital name, document type, date of collection, name and serial 
number for each document which was supposed to be recorded by the research assistants. 
Moreover, the checklist also contained data coding keys as continuous variables: total number 
of drugs prescribed in each document, number of drugs belonging to EDL, number of drugs 
out of EDL, number of drugs written in trade names, number of drugs written in scientific 
names, number of drugs written in English language, and number of drugs not written in 
English language. Each document type data was entered in a separate SPSS file, analyzed, and 
interpreted alone.     
 
The following Figure explains the data collection process. 
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Figure (3.1): Sampling process for data collection tools. 
3.7.  Eligibility criteria 
3.7.1. Inclusion criteria 
3.7.1.1. Physicians 
All physicians working in the emergency departments, out-patient clinics, in-patient 
departments and practicing prescribing drugs for patients in the study settings were included in 
the sample. 
Data 
sampling 
process 
Knowledg & Attitude  Questionnaire 
Stratified 
Proportionat sample 
for each hospital 
Al-Shifa, Nasser,EGH, 
Al-Aqsa, and Kamal 
Odwan 
Prescribing behavior Checklist 
Emergency 
department reports 
200 report from each 
hospital 
In-patient discharge 
report 
200 report  from each 
hospital 
In-patient 
medication sheet  
200 report  from each 
hospital 
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3.7.1.2. Prescribing forms 
 All forms; emergency department reports, in-patient discharge reports, and in-patient 
medication sheets including prescribed drugs with a clear handwriting were included in the 
sample. 
3.7.2. Exclusion criteria 
3.7.2.1. Physicians 
- Managerial and administrative level physicians who do not practice prescribing drugs. 
- External contract consultants. 
- Histopathology physicians. 
- Radiologists.  
- Forensic physicians (autopsy). 
- Newly moved physicians to the hospitals from managerial or administrative directorates 
of MoH. 
3.7.2.2. Prescribing forms  
- Forms not including drug management.  
- Forms not written in a clear handwriting. 
3.8. Scientific rigor  
Reliability, face validity, content validity, and pilot study were discussed in this section. 
3.8.1. Reliability  
Before the start of the data collection process, the researcher asked colleagues in hospital 
pharmacies for help. The researcher made a field visit to the study settings to understand the 
flow process of all paper forms included in the study and to determine the suitable point at 
which data can be collected easily without affecting the process of work in these hospitals. 
The researcher organized meetings with patient representative officers in each hospital and 
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made all the arrangements necessary to facilitate data collection process and detected the 
optimal time for data collection: from patient files, in-patient medication sheets and discharge 
reports optimal time was optimally collected at 12:30 PM for in-patients discharged in the 
same day, emergency department forms of the previous day was optimally collected and 
recorded at 9 AM.  
 Then the researcher implemented on the job training for twelve volunteer data collectors to 
make sure the data collection is done properly and being reliable. The researcher has trained 
the assistants on how to fill data in checklist. Many difficulties faced the data collectors during 
the data collection process. The pilot phase revealed a problem related to the time required to 
fill in the checklist. It was found that the checklist requires a long writing time which was so 
difficult to complete in the current flow process of work in hospitals without interrupting the 
work. The researcher found it a must to make some modification in the process of data 
collection while maintaining the same quality and value of the collected data itself. 
The researcher found that, the problem can be resolved by skipping the step of manual data 
recording on paper checklists through getting photos for these original documents and 
completing the process of data entry directly on software file later at home. This solution was 
applicable only by using the android smart phones application Whatsapp
®
, based upon, 
instead of manual data recording on papers, the assistants became able to capture photos for 
these documents easily and send it to the researchers phone, the researcher then moved it from 
his phone to computer. Away from hospitals rush hours the researcher archived the data in his 
computer properly according to the date of receiving, document type, and hospital name. One 
of the benefits gained through applying this process was to decrease the possibility of data 
transcription errors between the data collector and the data entry process by deleting 
unnecessary steps and reducing recording time. The researcher trained the data collectors on 
the new process of work which took no more than 10-15 minutes per day compared to the 
previous process that used to take more than 40 minutes a day. The researcher used to call data 
collectors daily to follow up and overcome obstacles and difficulties they faced during data 
collection process. The researcher used to check and review all the entire data sent by the data 
collectors day-by-day. In addition, the researcher entered the data into SPSS by himself. After 
finishing the data entry process and finalizing the study analysis, all photographic images were 
deleted from the researcher‘s computer.  
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3.8.2. Face validity  
Face validity is the degree to which the general appearance of certain test is sensationally 
consistent with and providing relevant answers to its purpose of measurement. The 
questionnaire was structured in an organized way to allow easy and smooth data collection and 
entry. During the validation process, the questionnaire lay out was reviewed and formatted 
several times until a final version looked elegant.  
3.8.3. Content validity  
To ensure that the content of the questionnaire is valid and provide an adequate 
representativeness of what researcher need to measure, because of that content validity usually 
depends on the judgment of experts in the fields. Thirteen experts with different backgrounds 
participated valuably in the questionnaire and checklists evaluation and validation process 
(Annex 7). The content validation aimed to assess the relevance of each domain, the 
importance of each particular item, and to check if the contents of the questionnaire seem 
appropriate to its intended purpose and overall aim, moreover, to ensure the statistical 
consistency and capability to analyze data properly. Additionally, the researcher considered all 
experts' feedback and comments. Thus, the final version of the questionnaire and checklists 
incorporated all the experts‘ feedback. Modifications were done including rephrasing 
questions, changing the order of some questions, adding new questions, and removing 
irrelevant questions.  
3.8.4. Pilot study  
A pilot study was conducted before the actual data collection started, with an aim of exploring 
the appropriateness and reliability of the questionnaire, piloting also aimed to have an idea of 
what obstacles might face the researcher during the data collection, such as the accessibility to 
participants or records, and to minimize the non-response rate. The pilot study was conducted 
on 10% of the main study sample. The pilot study sample consisted of 32 physicians; 18 
physicians distributed at Al-Shifa hospital, and 14 physicians at EGH.  
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3.9. Data Collection process 
Data were collected by the researcher and the volunteer data collectors from physicians and 
observational checklist for in-patient medication sheets, in-patient discharge reports, and 
emergency departments reports. The data collectors were trained on how to capture and send 
photos of the documents mentioned above, and how to distribute and collect questionnaires. 
Along with receiving training on how to collect data, data collectors also have received full 
information about the purpose, the objectives, and the methodology of the study. All 
participated physicians and documents were selected randomly through simple random 
technique. After receiving full information about the study purposes and objectives, physicians 
were informed that their participation is optional and they have the right not to answer any 
question.  
3.10. Response rate  
To increase study strength 360 questionnaires were distributed. 290 questionnaires were 
returned. Therefore, the response rate was 80.5 %.  
3.11. Data entry and statistical analysis  
The researcher used the Statistical Package of Social Science (windows version 20, SPSS, 
Chicago, USA) program to run descriptive and inferential statistics. The researcher has 
developed database for data entry, the variables were coded then entered into the computer.  
Data cleaning was conducted to check for any missing or error in data entry (through running 
frequency analysis).  All suspected or missed values were checked by revising the available 
data collection forms. The collected data (questionnaires and drugs prescribing forms) were 
organized and analyzed based on the objectives of the study. To detect the differences and 
assess the significant relationships among variables, the following analysis methods were 
performed:  
1. Frequency distribution, 
2. Cross tabulation, 
3. General scores, 
4. Mean percentages, 
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5. Chi-square test, 
6. Anova and Post-Hoc test  
The researcher determines the P value to be (˂0. 05%) with 95% confidence level.  
3.12. Ethical and administrative considerations 
During all stages, the researcher was committed to all ethical consideration required to 
conduct the study. Ethical approval (Helsinki committee approval) was obtained from the 
Palestinian health Research Council in Gaza (Annex 8). In addition, an official approval was 
obtained from the MoH relevant authorities: General Directorate of Human Resource, General 
Directorates of Hospitals, and Hospitals management (Annex 9). Every participant in the 
study received a complete explanation about the research purposes and confidentiality and 
about the optional participation in the study. All the ethical considerations were observed. 
Respect for people and human rights, respect for truth, and confidentiality were maintained. 
3.13. Limitations of the Study 
The researcher reported the following constraints:  
1. Probability of improper reporting in the official documents in hospital. 
2. Current instability of the health care system due to political and economic conditions. 
3.  All the questions in the questionnaire are closed-ended which may hinder some 
important points on knowledge and practice of the participating physicians. 
3.14. Obstacles faced the researcher 
1. Limited availability of up-to-date journals and books about the title relevant to the 
country context and situation.  
2. Time factor.  
3. Lack of funding. The study is self-funded.  
4. The problem of electricity blackouts which limited the access hours to the internet.  
5. The use of smart phones camera instead of using professional cameras led to the 
existence of some poor quality images. 
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6. It was observed that some physicians used to record medications in places other than 
places specified for that, as well as to record other medical data in designated places 
for drugs. 
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Chapter (4) 
Findings 
This chapter presents the main findings of the statistical analysis of the data and the 
interpretation of the main results. It begins by outlining the main descriptive and statistical 
findings of the semi-structured questionnaires followed by the findings from the three 
checklists.  The first checklist was used to extract data from in-patient medication sheets 
(admitted cases); the second checklist was used to extract data from emergency department 
reports-discharge sheet of emergency rooms; and the third checklist was used to extract data 
from in-patient discharge reports (IPDRs). 
4.1. Descriptive findings of the questionnaires 
Out of the total number of collected 296 questionnaires, 111 questionnaires were collected 
from Al-Shifa hospital, which represents 37.5% of the total sample, 69 questionnaires were 
collected from Nasser hospital, which represents 23.3% of the total sample, 45 questionnaires 
were collected from EGH hospital, which represents 15.2% of the total sample, 31 
questionnaires were collected from Kamal Odwan hospital, which represents 10.4% of the 
total sample, and 40 questionnaires were collected from Al-Aqsa hospital, which represents 
13.5% of the total sample. 
4.1.1. Participants characteristics 
4.1.1.1.  Socio-demographic characteristics of the study participants  
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Table (4. 1): Distribution of study participants by selected socio-demographic 
characteristics 
Characteristic No. %  
1- Marital status of participants 
Single 16 5.4  
Married 269 90.9  
Others 11 3.7  
Total 296 100.0 
2- Age groups of participants 
22 - 35 years 56 18.9  
36 - 50 years 207 69.9  
Older than 50 years 33 11.1  
Total 296 100.0  
Mean: 41.8  SD: 7.613 
3- Residency Governorate of participants 
North 39 13.2  
Gaza 108 36.5  
Middle 51 17.2  
KhanYonis 74 25.0  
Rafah 24 8.1  
Total 296 100.0  
 
Regarding the marital status of the study participants, as shown in the Table (4.1), the 
majority of study participants (90.9%) were married at the time of data collection and only 
5.4% of the study participants were single at the time of data collection, while divorced or 
widowed physicians represented 3.7% of the study participants at the time of data collection. 
Regarding the age of the study participants, as shown in the Table (4.1), the overall mean age 
of the study participants was 41.8 years with (SD: 7.613, Range: 36), the most common age 
group was 36-50 years old. About 19 % of the study participants were younger than 35 years 
old, while 11.1% of the study participants were older than 50 years old. Regarding the 
residency of the study participants, Table (4.1) showed that 36.5% of the study participants 
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were residents of Gaza governorate; 25% were residents of Khan Younis governorate, 17.2% 
were residents of Middle region governorates, 13.2% were residents of North Gaza 
governorates, and 8.1% were residents of Rafah governorate.  
 
With regard to the gender of the study participants, out of the 296 participants, 262 were male 
physicians (89%), while 34 (11%) were female physicians Figure (4.1).  
4.1.1.2. Work characteristics of the study participants 
 
 
 
 
 
 
 
 
 
89% 
11% 
Figure (4.1) Distribution of the study participants by 
Gender 
Male
Female
 41 
 
 
Regarding to the academic qualifications of the study participants, as shown in the Figure 
(4.2), nearly one third of the study participants (31%) had a Bachelor degree (BSc), 43% of 
the study participants had master‘s degree or high specialized diploma, 21% of the study 
participants had Board of Residency programs, and only 5% of the study participants had 
Doctor of Philosophy degree (Ph.D.). 
31% 
43% 
5% 
21% 
Figure (4.2) Distribution of participants by academic 
qualifications  
BSc
MSc  or High diploma
Ph.D
Board
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As shown in the Figure (4.3), nearly one third of the study participants (37%) had an internal 
medicine specialty, another one third of the study participants (32%) had a specialty in 
surgical field, 10% of the study participants had specialty in pediatric field, 12% of the study 
participants had specialty in Obstetrics and Gynecology field, 7% of the study participants had 
specialty in the intensive care units (ICU) field, and only 2% of the study participants had 
specialty in burns management field. 
 
Table (4.2): Years of work experience of the study participants 
Variable Mean Mode SD Minimum Maximum 
Governmental work experience 13.3 15 6.407 2 35 
Private work experience 8 5 6.032 0 34 
 
 
Regarding the total years of work experience of the study participants in the governmental 
hospitals, as shown in the Table (4.2), the average years of work experience of the study 
participants in the governmental hospitals was 13.3 years (with a minimum of 2 years and 
37% 
32% 
10% 
12% 
2% 7% 
Figure (4.3) Distribution of participants by specialty  
Internal medicine
Surgical
Pediatrician
Obstetric and gyn.
Burns
ICU
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maximum of 35 years, SD:6.407). The average years of private work experience of the study 
participants was 8 years (with a minimum of zero years and maximum of 34 years, SD: 
6.032).  
 
 
 
Concerning the hospital managerial position of the study participants, Figure (4.4) showed 
that 78% of the study participants had no managerial positions, 4% of the study participants 
had a head of division managerial position, 15% of study participants had a head of section 
managerial position, and only 3% of the study participants had a head of department 
managerial position. 
4.1.1.3. Other characteristics of the study participants 
 
3% 
15% 
4% 
78% 
Figure (4.4) Distribution of participants by managerial 
positions 
Director of Department
Head of Section
Head of Division
No managerial position
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Concerning the private work of the study participants, more than half of the study participants 
(55%) had private work, as shown in the Figure (4.5), 28% of study the participants had 
private clinics, 19% of the study participants work in NGO clinics, 2% of the study 
participants work in academic institutions, 2% of the study participants work in other 
institutions, and 4% of the study participants had more than one type of the mentioned private 
work types at the same time.  
From the researcher perspective, the percentage of physicians who had a private work in 
addition to the governmental work is high. The main reason for such high percentage could be 
due to the lack of laws that regulate the work of the governmental physicians in the private 
sector. Another reason could be the halt in salary payments due the Palestinian political rift 
which led physicians to look for alternative sources of incomes.  
The work of the physician in the private sector may have negative impact on the quality of the 
provided health services; the work of the physician in more than one job may lead to high 
level of stress and fatigue. Moreover, physicians working in the private sectors are more likely 
28% 
19% 
2% 4% 
2% 
45% 
Figure (4.5) Distribution of participants by private work 
types 
Private Clinic
NGO Clinics
Academic Teaching
More than one work
Others
Non
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to be exposed to the promotional activities of pharmaceutical drug companies. Eventually, this 
may reduce physicians‘ compliance with the EDL.   
 
 
Concerning the exposure of the study participant‘s to the advertisement activities from 
medical representatives of pharmaceutical drug companies, as shown in the Figure (4.6), the 
study found that physicians at the study settings are heavily exposed to medical representative 
activities from pharmaceutical drug companies. 77% of the study participants were exposed to 
medical representative activities within the study settings. The highest percentage of exposure 
was reported at EGH hospital, as indicated by 95% of the hospital participants. The lowest 
percentage of exposure was reported at Kamal Odwan Hospital, as indicated by 65.5% of the 
hospital participants.  
Despite the MoH decisions and orders that restrict the presence of representatives of 
pharmaceutical drug companies in the MoH hospitals,  from the researcher point of view the 
71.43 
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72.50 
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high percentage of private medical representative‘s activity in the governmental hospitals 
could be caused by the limited role that the hospitals management, the General Directorate of 
Monitoring and Evaluation as well as the Licensing and Accreditation unit have been playing 
in monitoring and following up the activities of medical representative‘s within hospitals. It is 
worth mentioning that the General Directorate of Pharmacy does not revise the publications 
used by medical representatives in the promotional activities to assure their scientific value 
and credibility as being unbiased source of information.   
4.1.1.4. Knowledge of the study participants about EDL 
This part discusses the findings related to the knowledge of study participant‘s about EDL.  
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Table (4.3): Knowledge of the study participants about the EDL 
Variable Al-Shifa Nasser EGH 
Kamal 
Odwan 
Al-Aqsa Total 
1- Knowledge about the presence MoH-EDL 
Yes 
No. 68 50 36 20 27 201 
%  61.8% 73.5% 80.0% 66.7% 69.2% 68.8% 
No 
No. 15 6 3 4 1 29 
%  13.6% 8.8% 6.7% 13.3% 2.6% 9.9% 
Don't Know 
No. 27 12 6 6 11 62 
%  24.5% 17.6% 13.3% 20.0% 28.2% 21.2% 
Total 
No. 110 68 45 30 39 292 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2- Knowledge about the presence of hospital EDL 
Yes 
No. 46 29 26 14 22 137 
%  41.8% 42.6% 59.1% 45.2% 57.9% 47.1% 
No 
No. 23 18 8 7 6 62 
%  20.9% 26.5% 18.2% 22.6% 15.8% 21.3% 
Don't Know 
No. 41 21 10 10 10 92 
%  37.3% 30.9% 22.7% 32.3% 26.3% 31.6% 
Total 
No. 110 68 44 31 38 291 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
3- MoH-EDL is updated routinely 
Yes 
No. 31 27 18 12 8 96 
%  28.2% 39.1% 40.0% 38.7% 20.0% 32.5% 
No 
No. 18 10 10 5 7 50 
%  16.4% 14.5% 22.2% 16.1% 17.5% 16.9% 
Don't Know 
No. 61 32 17 14 25 149 
%  55.5% 46.4% 37.8% 45.2% 62.5% 50.5% 
Total 
No. 110 69 45 31 40 295 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
Regarding the study participants knowledge about the existence of MoH-EDL, as shown in the 
Table (4.3), only 68.8% of the study participants are aware of the existence of EDL in the 
MoH. The highest percent of knowledge about the existence of MoH-EDL was observed at 
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EGH hospital, as indicated by 80% of the hospital participants, while the lowest was observed 
at Al-Shifa hospital, as indicated by 61.8% of the hospital participants. The finding of the 
study is consistent with the findings of Mariam and Colleagues (2015). 
 With regard to the study participant‘s knowledge about the existence of hospital EDL, as 
shown in the Table (4.3), physician‘s knowledge about the existence of hospital EDL was not 
high, as less than half of the study participants (47.1%) are aware of the existence of hospital 
EDL. The highest percent of knowledge about the existence of hospital EDL was observed at 
EGH hospital, as indicated by 59.1% of the hospital participants, while the lowest was 
observed at Al-Shifa hospital, as indicated by 41.8% of the hospital participants. From the 
researcher‘s perspective, this finding may result from the lack of EDL training programs in the 
MoH for newly employed physicians as well as the absence of continuous education programs 
for all employees in general.  
Regarding the knowledge of the study participants about MoH-EDL updating process, as 
shown in the Table (4.3), only one third of the study participants (32.5%) know that MoH-
EDL is regularly updated. The highest percentage of knowledge about MoH-EDL updating 
process was observed at EGH hospital, as indicated by 40% of the hospital participants, while 
lowest percentage of knowledge was observed at Al-Aqsa hospital, as indicated by 20% of the 
hospital participants. 
The main reasons that could explain limited physicians knowledge about the MoH-EDL and 
hospital EDL are: (1). MoH did not implement training programs for physicians on the 
concept and content of the EDL for 13 consecutive years; (2). EDL and other related topics are 
not included in the educational curriculum of the faculties of medicine in the Palestinian 
universities; (3). The absence of EDL related topics in the training programs for newly 
recruited physicians; and  (4). The limited availability hard copies of the EDL within hospitals. 
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Table (4.4): Knowledge of the study participants about the EDL updating and training 
process 
Variable Al-Shifa Nasser EGH 
Kamal 
Odwan 
Al-Aqsa Total 
1- Participants receive training on EDL contents 
Yes 
No. 17 9 4 3 3 36 
%  15.7% 13.2% 9.1% 10.0% 7.5% 12.4% 
No 
No. 91 59 40 27 37 254 
%  84.3% 86.8% 90.9% 90.0% 92.5% 87.6% 
Total 
No. 108 68 44 30 40 290 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2- Entity responsible for setting up  hospital EDL 
Central P&T 
Committee 
No. 21 8 5 2 8 44 
%  19.4% 11.6% 11.4% 6.5% 20.0% 15.1% 
Hospital P&T 
Committee 
No. 18 12 7 3 7 47 
%  16.7% 17.4% 15.9% 9.7% 17.5% 16.1% 
Hospital Manager 
No. 3 1 0 1 0 5 
%  2.8% 1.4% 0.0% 3.2% 0.0% 1.7% 
Hospital 
Pharmacy 
No. 6 8 2 6 5 27 
%  5.6% 11.6% 4.5% 19.4% 12.5% 9.2% 
Don't Know 
No. 60 40 30 19 20 169 
%  55.6% 58.0% 68.2% 61.3% 50.0% 57.9% 
Total 
No. 108 69 44 31 40 292 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
3- Attendance to refreshing lectures on the EDL 
Always 
No. 9 0 1 4 0 14 
%  8.4% 0.0% 2.3% 13.8% 0.0% 4.9% 
Rarely 
No. 30 25 16 5 10 86 
%  28.0% 37.9% 36.4% 17.2% 25.0% 30.1% 
No 
No. 68 41 27 20 30 186 
%  63.6% 62.1% 61.4% 69.0% 75.0% 65.0% 
Total 
No. 107 66 44 29 40 286 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
With respect to the training process on EDL, Table (4.4) shows that only 12.4% of the study 
participants received training on EDL while, the majority of the study participants (87.6%) did 
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not receive any training on EDL. The highest percentage of participants who received training 
on EDL was observed at Al-Shifa hospital, as indicated by 15.7% of the hospital participants. 
The lowest percent of the study participants who received training on EDL was observed at 
Al-Aqsa hospital, as indicated by 7.5% of the hospital participants. 
 According to Table (4.4), the study participants were confused about the entity responsible 
for developing of hospital EDL. Only 16.1% of the study participants chose correctly the 
Hospital P & T Committee. The highest percentage of knowledge about the entity responsible 
for developing of hospital EDL was observed at Al-Aqsa hospital, as indicated by 17.5% of 
the hospital participants. The lowest percentage of knowledge about the entity responsible for 
developing of hospital EDL was observed at Kamal Odwan hospital, as indicated by 9.7% of 
the hospital participants. On the contrary, more than half of the study participants (57.9%) 
denied knowledge about the entity responsible for setting up hospital EDL, The highest 
percentage of lack of knowledge was observed at EGH hospital, as indicated by 68.2% of the 
hospital participants.  
With regard to the study participants‘ attendance to the EDL refreshing lectures at the 
hospitals, Table (4.4) shows that around two thirds (65%) of the study participants have never 
attended any EDL refreshing lectures at all. The highest percentage of non-attendant 
participants was observed at Al-Aqsa hospital, as indicated by 75% of the hospital 
participants, while the lowest percentage of non-attendants was observed at EGH hospital, as 
indicated by 61.4% of the hospital participants. 
 
4.1.1.5. Participant’s practices and attitude towards EDL 
The findings in this part reflect the attitude of study participant‘s about EDL.  
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Table (4.5):  Participant’s practices and attitude toward EDL 
Variable  
Strongly 
Disagree 
Disagree Uncertain Agree 
Strongly 
Agree 
Mean 
Mean % of 
positive 
responses 
1- EDL is necessary for provision of equitable health services 
No. 12 13 23 166 81 
3.99 79.8 
% 4.1 4.4 7.8 56.3 27.5 
2- EDL is necessary for provision of quality health services 
No. 7 12 35 145 95 
4.05 81 
% 2.4 4.1 11.9 49.3 32.3 
3- EDL is necessary to reduce wasting of health care resources 
No. 5 21 35 163 67 
3.91 78.2 
% 1.7 7.2 12.0 56.0 23.0 
4- EDL is necessary to prevent patient harm 
No. 7 25 55 148 58 
3.77 75.4 
% 2.4 8.5 18.8 50.5 19.8 
5- EDL selection criteria are scientifically based 
No. 10 15 85 131 50 
3.67 73.4 
% 3.4 5.2 29.2 45.0 17.2 
6- EDL must include all drugs that patient needs 
No. 3 12 23 145 109 
4.18 83.6 
% 1.0 4.1 7.9 49.7 37.3 
7- EDL contain the majority of needed drugs 
No. 11 52 84 107 35 
3.36 67.2 
% 3.8 18.0 29.1 37.0 12.1 
8- Prescribe drugs out of hospital EDL in the work  
No. 3 20 35 169 65 
3.93 78.6 
% 1.0 6.8 12.0 57.9 22.3 
9- Always advise patients to buy drugs that are not listed  in the EDL 
No. 54 120 46 57 11 
2.48 49.6 
% 18.8 41.7 16.0 19.8 3.8 
10- Advise patient to buy drugs from the market when it is out of stock in the hospital 
No. 8 21 24 188 45 
3.84 76.8 
% 2.8 7.3 8.4 65.7 15.7 
Mean: 76.85 %                            SD: 3.247  
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As shown in Table (4.5), there was a positive attitude about the EDL, the overall mean of the 
study participant's positive attitude about EDL was 76.85% (SD: 3.247).  
As shown in the Table (4.5), the majority of the study participants (83.8%) agreed or strongly 
agreed on the value and necessity of EDL for provision of equitable health services within 
hospitals. Only 16.2% of the study participants were either uncertain or disagreed on the 
benefits of using EDL drugs for achieving equitable health services. The mean percentage was 
79.8%. Additionally, as shown in the Table (4.5), the majority of the study participants 
(81.6%) agreed or strongly agreed on the necessity of EDL for provision of quality health 
services. Only 6.5% of the study participants disagreed on the benefits of using EDL for 
achievement of quality health services. The mean percentage was 81%. 
As shown in the Table (4.5), more than two thirds of the study participants (79%) agreed or 
strongly agreed that the use of EDL reduces wasting of health care resources.  While, only 
8.9% of the study participants disagreed on the importance of EDL in reducing wasting of 
health care resources. The mean percentage was 78.2%. Furthermore, as shown in the Table 
(4.5), 70.3% of the study participants agreed or strongly agreed that the use of EDL prevents 
patient harm, while 10.9% of the study participants disagreed on that. The mean percentage 
was 75.4%. 
 Regarding the general perception of the study participants about the EDL selection criteria, as 
shown in the Table (4.5), two thirds of the study participants (62.2%) agreed or strongly 
agreed that the listed drugs in the EDL are selected on scientific bases, while 29.2% of the 
study participants were uncertain. The mean percentage was 73.4%. Moreover and 
unexpectedly, as shown in the Table (4.5), most of the study participants (87%) revealed that 
they were not aware of the real EDL selection criteria and agreed or strongly agreed that EDL 
must include all drugs needed to treat admitted patients. The mean percentage was 83.6%. On 
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the other hand, as shown in the Table (4.5), around one half of the study participants (50.9%) 
were either uncertain or disagreed that EDL contain the majority of needed drugs for treatment 
of admitted patients in the hospital. The mean percentage was 67.2%.  
Furthermore, as shown in the Table (4.5), on practical basis, the majority of the study 
participants (80.2%) revealed that they prescribe drugs not included in the EDL during their 
work in the hospitals. The mean percentage was 76.8%. These drugs were minimal, only 
23.6% of the study participants agreed that they always advise patients to buy drugs from the 
market instead of hospital EDL drugs. The mean percentage was 49.6%. Finally, Table (4.5) 
shows that, the majority of the study participants (81.4%) agreed or strongly agreed on telling 
patients to buy drugs from the private market when it is out of stock in the hospital, while 
8.4% of the study participants were uncertain of doing that. The mean percentage was 76.8%. 
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4.1.1.6. Physicians interaction with hospitals’ pharmacies 
 
Table (4.6): Participants communication with hospital Pharmacy 
Variable  Al-Shifa Nasser EGH 
Kamal 
Odwan 
Al-Aqsa Total 
1- Physicians’ communication with pharmacists 
Always 
No. 17 17 8 6 14 62 
%  15.7% 25.0% 17.8% 20.0% 35.9% 21.4% 
Rarely 
No. 51 35 16 16 18 136 
%  47.2% 51.5% 35.6% 53.3% 46.2% 46.9% 
Don't 
No. 40 16 21 8 7 92 
%  37.0% 23.5% 46.7% 26.7% 17.9% 31.7% 
Total 
No. 108 68 45 30 39 290 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2- Physicians’ response to pharmacists recommendations in prescribing EDL 
Always 
No. 40 18 9 8 17 92 
% 37.4% 27.7% 21.4% 27.6% 42.5% 32.5% 
Rarely or Do not 
No. 67 47 33 21 23 191 
% 62.6% 72.3% 78.6% 72.4% 57.5% 67.5% 
Total 
No. 107 65 42 29 40 283 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
3- Participants sources of drugs information 
Hospital Pharmacist 
No. 34 16 14 11 4 79 
% 31.5% 24.6% 32.6% 37.9% 10.8% 28.0% 
Medical 
Representative 
No. 9 1 3 2 0 15 
% 8.3% 1.5% 7.0% 6.9% 0.0% 5.3% 
Colleague 
No. 7 3 2 3 1 16 
% 6.5% 4.6% 4.7% 10.3% 2.7% 5.7% 
A text book 
No. 18 11 10 1 3 43 
% 16.7% 16.9% 23.3% 3.4% 8.1% 15.2% 
Internet 
No. 19 16 5 6 13 59 
% 17.6% 24.6% 11.6% 20.7% 35.1% 20.9% 
More than one source 
No. 21 18 9 6 16 70 
% 19.4% 27.7% 20.9% 20.7% 43.2% 24.8% 
Total 
No. 108 65 43 29 37 282 
% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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With regard to the Physicians‘ communication with hospital pharmacists, Table (4.6) shows 
that, the majority of the study participants (78.6%) do not communicate with pharmacists 
properly or regularly. The highest percentage of communication was observed at Al-Aqsa 
hospital, as indicated by 35.9% of the hospital participants. The lowest percentage of 
communication was observed at Al-Shifa hospital, as indicated by 15.7% of the hospital 
participants. 
Table (4.6) revealed that physicians do not respond to pharmacists‘ recommendations as more 
than two thirds of the study participants (67.5%) said that they do not respond to pharmacists‘ 
recommendations in prescribing drugs from EDL. The highest percentage of participants‘ 
response to pharmacists‘ recommendations to prescribe EDL drugs was observed at Al-Aqsa 
hospital, as indicated by 42.5% of the hospital participants. The lowest percentage of 
participants‘ response to hospital pharmacist recommendations was observed at EGH hospital, 
as indicated by 21.4% of the hospital participants. 
4.1.1.7. Participant’s sources of drugs information 
 
Finally, regarding study participants sources of drug information, Table (4.6) reveals that the 
study participants do not have a particular source of drug information. Unexpectedly, the most 
common drug information source was the hospital pharmacists as indicated by 28% of the 
study participants. The highest percentage of the study participants who recognized the 
hospital pharmacists as their drug information source was observed at Kamal Odwan hospital, 
as indicated by 37.9% of the hospital participants. The lowest percentage was observed at Al-
Aqsa hospital, as indicated by 10.8% of the hospital participants. This finding is inconsistent 
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with several studies in other countries (Zeidan, 2015; García et al., 2011; Kamal et al., 2014; 
Thriemer et al., 2013; Kargar et al., 2016; Quet et al., 2015). It implies that hospital 
pharmacists within the Palestinian context are more recognized by the physicians as a trusted 
source of drug information. 
4.1.2. Health facility characteristics 
4.1.2.1. Hospital management 
This part highlights the important aspects related to EDL updating and dissemination process.  
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Table (4.7): Participants opinions about aspects related to EDL updating & 
dissemination 
Variable  Al-Shifa Nasser EGH 
Kamal 
Odwan 
Al-Aqsa Total 
1- Participants receive hospitals EDL updates 
Seasonal 
No. 2 7 0 1 2 12 
%  1.9% 10.4% 0.0% 3.3% 5.1% 4.2% 
Annually 
No. 10 10 2 5 4 31 
%  9.3% 14.9% 4.4% 16.7% 10.3% 10.7% 
Every two- years 
No. 7 1 0 1 0 9 
%  6.5% 1.5% 0.0% 3.3% 0.0% 3.1% 
Don't receive 
updates 
No. 89 49 43 23 33 237 
%  82.4% 73.1% 95.6% 76.7% 84.6% 82.0% 
Total 
No. 108 67 45 30 39 289 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2- Participants receive MoH- EDL updates 
Seasonal 
No. 0 3 0 1 1 5 
%  0.0% 4.3% 0.0% 3.4% 2.5% 1.7% 
Annually 
No. 8 9 2 6 5 30 
%  7.5% 13.0% 4.4% 20.7% 12.5% 10.4% 
Every -two years 
No. 5 0 0 0 1 6 
%  4.7% 0.0% 0.0% 0.0% 2.5% 2.1% 
Don't receive 
updates 
No. 93 57 43 22 33 248 
%  87.7% 82.6% 95.6% 75.9% 82.5% 85.8% 
Total 
No. 106 69 45 29 40 289 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
3- Participants have copy of hospital EDL 
Paper 
No. 7 8 3 3 7 28 
%  8.0% 15.7% 7.9% 12.5% 25.0% 12.2% 
Electronic 
No. 3 0 0 0 0 3 
%  3.4% 0.0% 0.0% 0.0% 0.0% 1.3% 
Paper & Electronic 
No. 4 2 0 0 1 7 
%  4.5% 3.9% 0.0% 0.0% 3.6% 3.1% 
Do not have any 
copy 
No. 74 41 35 21 20 191 
%  84.1% 80.4% 92.1% 87.5% 71.4% 83.4% 
Total 
No. 88 51 38 24 28 229 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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With regard to the relationship between study participants and their hospital management, 
Table (4.7) shows that the majority of the study participants (82%) did not received any 
hospital EDL updates. The highest percentage of the study participants who did not receive 
any updates was observed at EGH hospital, as indicated by 95.6% of the hospital participants. 
The lowest percentage of the study participants who did not receive any updates was observed 
at Nasser hospital, as indicated by 73.1% of the hospital participants. 
In addition, Table (4.7) revealed that there was a communication gap between the study 
participants and the management (MoH management and hospital management) in the field of 
disseminating MoH-EDL updates. Table (4.7) shows that the majority of the study 
participants (85.8%) did not received any MoH-EDL updates. The highest percentage of the 
study participants who did not received any MoH-EDL updates was observed at EGH hospital, 
as indicated by 95.6% of the hospital participants. The lowest percentage of the study 
participants who did not received any MoH-EDL updates were observed at Kamal Odwan 
hospital, as indicated by 75.9% of the hospital participants. 
Moreover, regarding to the presence of hospital EDL copies available to the study participants 
at work, as shown in the Table (4.7), the majority of the study participants (83.4%) do not 
have hard or soft copies of hospital EDL at work. The highest percentage of the study 
participants who do not have any copy of hospital EDL was observed at EGH hospital, as 
indicated by 92.1% of the hospital participants. The lowest percentage of participants who do 
not have any copy of hospital EDL was observed at Al-Aqsa hospital, as indicated by 71.4% 
of the hospital participants. 
This finding is inconsistent with Fattouh and Abu Hamad study (1010) that showed that copies 
of EDL are less available in the hospitals when compared to primary health care centers. 
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From the researcher‘s perspective, the limited role of the hospital Pharmacy and Therapeutics 
Committee in carrying out the tasks entrusted to it is probably the main reason for physicians 
not to get the hospital EDL updates. As a result of these committees ineffectiveness mainly, 
copies of both lists are not available to the physicians working at the hospital.  
Table (4.8): Participants opinions about hospital management efforts related to EDL  
Variable  Al-Shifa Nasser EGH 
Kamal 
Odwan 
Al-Aqsa Total 
1- Hospital management encourages physicians to be compliant with EDL 
Always 
No. 17 15 1 4 10 47 
%  15.9% 22.4% 2.4% 13.8% 25.0% 16.5% 
Rarely or Do not 
No. 90 52 41 25 30 238 
%  84.1% 77.6% 97.6% 86.2% 75.0% 83.5% 
Total 
No. 107 67 42 29 40 285 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2- Hospital organizes EDL refreshing lectures 
Yes 
No. 8 6 7 3 1 25 
%  7.5% 9.2% 15.9% 10.3% 2.5% 8.8% 
No 
No. 67 43 31 21 23 185 
%  62.6% 66.2% 70.5% 72.4% 57.5% 64.9% 
Don't Know 
No. 32 16 6 5 16 75 
%  29.9% 24.6% 13.6% 17.2% 40.0% 26.3% 
Total 
No. 107 65 44 29 40 285 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
Table (4.8) reveals that hospital management do not take their role in encouraging physicians 
adequately to be compliant with EDL. Table (4.8) showed that most of the study participants 
(83.5%) felt that they were not encouraged properly by hospital management to be compliant 
with EDL drugs. The highest percent of the study participants who felt that they were not 
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encouraged properly by hospital management was observed at EGH hospital, as indicated by 
97.6% of the hospital participants. The lowest percent of the study participants who felt that 
they were not encouraged properly by hospital management was observed at Al-Aqsa hospital, 
as indicated by 75% of the hospital participants. Regarding the hospital management role in 
human resource development, Table (4.8) reveals that hospitals managements in the study 
setting are not doing their assigned role in organizing EDL awareness and training sessions to 
encourage physicians to prescribe EDL drugs. Table (4.8) showed that more than two thirds of 
the study participants (64.9%) confirmed that hospital management does not arrange any EDL 
refreshing lectures or sessions. The highest percentage of the study participants who have 
indicated not having any EDL refreshing lectures was observed at Kamal Odwan hospital, as 
indicated by 72.4% of the hospital participants. The lowest percentage of the study 
participants who have indicated not having any EDL refreshing lectures was observed at Al-
Aqsa hospital, as indicated by 57.5% of the hospital participants. Based on the results of these 
answers, we can strongly conclude that the hospital management does not completely perform 
its assigned role in promoting physicians compliance with the EDL. This is probably due to 
several reasons, including frequent changes in hospital management; irregularities of salaries; 
limited incentives; and the absence of training activities. 
4.1.2.2. Pharmacy & Therapeutics committee 
This part reflects the study participant‘s impressions about the hospital pharmacy and 
therapeutics committee. 
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Table (4.9): Participants knowledge about treatment protocols in the hospital 
Variable  Al-Shifa Nasser EGH 
Kamal 
Odwan 
Al-Aqsa Total 
1- There are  treatment protocols in the hospital 
Yes 
No. 39 29 13 13 15 109 
%  37.1% 43.3% 29.5% 41.9% 38.5% 38.1% 
No 
No. 36 20 12 16 13 97 
%  34.3% 29.9% 27.3% 51.6% 33.3% 33.9% 
Don't Know 
No. 30 18 19 2 11 80 
%  28.6% 26.9% 43.2% 6.5% 28.2% 28.0% 
Total 
No. 105 67 44 31 39 286 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2- Treatment protocols location 
Hospital Library 
No. 1 0 0 0 0 1 
%  0.9% 0.0% 0.0% 0.0% 0.0% 0.3% 
Hospital ward 
No. 24 28 4 7 11 74 
%  22.0% 41.2% 8.9% 22.6% 28.2% 25.3% 
Pharmacy 
No. 17 11 11 6 6 51 
%  15.6% 16.2% 24.4% 19.4% 15.4% 17.5% 
Don't Know 
No. 65 29 29 18 22 163 
%  59.6% 42.6% 64.4% 58.1% 56.4% 55.8% 
Other places 
No. 2 0 1 0 0 3 
%  1.8% 0.0% 2.2% 0.0% 0.0% 1.0% 
Total 
No. 109 68 45 31 39 292 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
Regarding the participants‘ knowledge about the presence of treatment protocols, Table (4.9) 
shows that only one third of the study participants (38.1%) confirmed the presence of 
treatment protocols in the hospital. The highest percentage of the study participants who 
confirmed the presence of treatment protocols in the hospital was observed at Nasser hospital, 
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as indicated by 43.3% of the hospital participants. The lowest percentage of the study 
participants who confirmed the presence of treatment protocols in the hospital was observed at 
EGH hospital, as indicated by 29.5% of the hospital participants. This finding is consistent 
with Fattouh and Abuhamad study (2010) as well as the Bangladesh study conducted by Khan 
and Colleagues (2011). Moreover, Table (4.9) shows that more than half of the study 
participants (55.8%) do not know the location of the treatment protocols in the hospital. The 
highest percentage of the study participants who do not know the location of the treatment 
protocols in the hospital was observed at EGH hospital, as indicated by 64.4% of the hospital 
participants. The lowest percentage of the study participants who do not know the location of 
the treatment protocols in the hospital was observed at Nasser hospital, as indicated by 42.6% 
of the hospital participants. 
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Table (4.10): Participants knowledge about the role of Pharmacy &Therapeutics 
committee in the hospital 
Variable  Al-Shifa Nasser EGH 
Kamal 
Odwan 
Al-Aqsa Total 
1- There is Pharmacy &Therapeutics committee in the hospital 
Yes 
No. 34 38 21 10 20 123 
%  31.5% 56.7% 47.7% 34.5% 50.0% 42.7% 
No 
No. 16 1 0 4 2 23 
%  14.8% 1.5% 0.0% 13.8% 5.0% 8.0% 
Don't Know 
No. 58 28 23 15 18 142 
%  53.7% 41.8% 52.3% 51.7% 45.0% 49.3% 
Total 
No. 108 67 44 29 40 288 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2- Participants receive protocols from Pharmacy &Therapeutics committee 
Always 
No. 8 2 3 1 3 17 
%  7.5% 3.0% 6.8% 3.4% 7.5% 5.9% 
Rarely  
No. 39 28 16 14 15 112 
%  36.4% 42.4% 36.4% 48.3% 37.5% 39.2% 
Do not 
No. 60 36 25 14 22 157 
%  56.1% 54.5% 56.8% 48.3% 55.0% 54.9% 
Total No. 107 66 44 29 40 286 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
3- Pharmacy &Therapeutics committee arrange training program on EDL 
Always 
No. 11 3 2 2 2 20 
%  10.1% 4.6% 4.5% 7.1% 5.0% 7.0% 
Rarely 
No. 29 11 12 8 10 70 
%  26.6% 16.9% 27.3% 28.6% 25.0% 24.5% 
No 
No. 69 51 30 18 28 196 
%  63.3% 78.5% 68.2% 64.3% 70.0% 68.5% 
Total 
No. 109 65 44 28 40 286 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
4- Pharmacy &Therapeutics committee gives feedback about physicians compliance with 
EDL 
Always 
No. 13 6 4 3 5 31 
%  12.3% 9.2% 9.3% 10.3% 12.8% 11.0% 
Rarely 
No. 43 29 22 14 16 124 
%  40.6% 44.6% 51.2% 48.3% 41.0% 44.0% 
No 
No. 50 30 17 12 18 127 
%  47.2% 46.2% 39.5% 41.4% 46.2% 45.0% 
Total 
No. 106 65 43 29 39 282 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
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As shown in the Table (4.10), there was no adequate knowledge of physicians about the 
Hospital Pharmacy & Therapeutics committee (Hospital P&T committee). Table (4.10) 
revealed that only 42.7% of the study participants confirmed the presence of P&T committee 
at their hospitals. The highest percent of the study participants who confirmed the presence of 
Hospital P&T committee was observed at Nasser hospital, as indicated by 56.7% of the 
hospital participants. The lowest percent of the study participants who confirmed the presence 
of Hospital P&T committee was observed at Al-Shifa hospital, as indicated by 31.5% of the 
hospital participants. With regard to the communication between the Hospital P&T committee 
and the study participants, findings in the Table (4.10) revealed that, more than half of the 
study participants (54.9%) do not receive any treatment protocols from the Hospital P&T 
committee. The highest percentage of the study participants who have not received treatment 
protocols from the Hospital P&T committee was observed at EGH hospital, as indicated by 
56.8% of the hospital participants. The lowest percentage of the study participants who have 
not received treatment protocols from the Hospital P&T committee was observed at Kamal 
Odwan hospital, as indicated by 48.3% of the hospital participants. Table (4.10) illustrates 
that two thirds of the study participants (68.5%) do not know if the Hospital P&T committee 
have conducted any training programs on EDL in the hospitals. The highest percentage of the 
study participants who do not know if Hospital P&T committee have conducted any training 
programs on EDL in the hospitals was observed at Nasser hospital, as indicated by 78.5% of 
the hospital participants. The lowest percentage of the study participants who do not know if 
the Hospital P&T committee has conducted any training programs on EDL in the hospitals 
was observed at Al-Shifa hospital, as indicated by 63.3% of the hospital participants. 
 Finally, Table (4.10) showed that, only 11% of the study participants received feedback from 
the Hospital P&T committee related to compliance with EDL. The highest percent of the study 
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participants who received feedback from the Hospital P&T committee related to compliance 
with EDL was observed at Al-Aqsa hospital, as indicated by 12.8% of the hospital 
participants. The lowest percent of the study participants who received feedback for their 
compliance with EDL was observed at Nasser hospital, as indicated by 9.2% of the hospital 
participants. These findings suggest that the study participants have limited knowledge about 
the activities of the Hospital P&T Committee as well as their knowledge about its assigned 
roles. This may be due to the fact that P&T committees was established after the Palestinian 
political rift in 2007 and it was not able to do its assigned role due to that political rift .  
4.1.2.3. Hospital pharmacies 
Table (4.11), highlights aspects related to the current relation between the study participants 
and hospital pharmacists. 
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Table (4.11): Interaction between hospital pharmacists and participants 
Variable  Al-Shifa Nasser EGH 
Kamal 
Odwan 
Al-Aqsa Total 
1- Pharmacists inform physicians about the available drugs 
Daily 
No. 12 8 2 6 2 30 
%  11.1% 11.8% 4.4% 19.4% 5.1% 10.3% 
Weekly 
No. 18 8 3 6 5 40 
%  16.7% 11.8% 6.7% 19.4% 12.8% 13.7% 
Monthly 
No. 6 25 12 4 18 65 
%  5.6% 36.8% 26.7% 12.9% 46.2% 22.3% 
Do not Have Any 
No. 72 27 28 15 14 156 
%  66.7% 39.7% 62.2% 48.4% 35.9% 53.6% 
Total 
No. 108 68 45 31 39 291 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2- Pharmacists encourage physicians  to be compliant with EDL 
Always 
No. 19 11 7 9 10 56 
%  17.6% 16.4% 15.9% 31.0% 25.0% 19.4% 
Rarely or Do not 
No. 89 56 37 20 30 232 
%  82.4% 83.6% 84.1% 69.0% 75.0% 80.6% 
Total 
No. 108 67 44 29 40 288 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
Table (4.11) reveals that, hospital pharmacists neither inform nor update physicians 
adequately about the available drugs; half of the study participants (53.6%) indicated that 
pharmacists do not update them about the available drugs in the hospital. The highest 
percentage of the study participants who have not received any information about the available 
drugs in the hospital was observed at Al-Shifa hospital, as indicated by 66.7% of the hospital 
participants. The lowest percent of the study participants who have not received any 
information about the available drugs in the hospital was observed at Al-Aqsa hospital, as 
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indicated by 35.9% of the hospital participants. Moreover, Table (4.11) reveals that the 
hospital pharmacists are not doing their assigned role in encouraging physicians adequately to 
prescribe EDL drugs. Most of the study participants (80.6%) revealed that they do not feel 
encouraged by hospital pharmacists to prescribe drugs from EDL. The highest percentage of 
the study participants who have not felt an encouragement by the hospital pharmacists to 
prescribe EDL drugs was observed at EGH hospital, as indicated by 84.1% of the hospital 
participants. The lowest percentage of the study participants who have not felt an 
encouragement by the hospital pharmacists to prescribe EDL drugs was observed at Kamal 
Odwan hospital, as indicated by 69% of the hospital participants. In spite of the existence of 
policies and procedures manual for hospital pharmacies (called pharmaceutical care guide in 
hospitals) since the year 2008 and the distribution of hard copies of this guide to each hospital 
pharmacist, the surveyed physicians believed that the hospital pharmacist‘s activity is still far 
below the expectations. Perhaps this is due to the lack of implementation of training activities 
for the hospital pharmacists on the contents of this guide. Moreover, it might be due to the fact 
that the old version of the mentioned guide does not contain detailed policies and procedures 
to deal with all the work carried out by the hospital pharmacists.  
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4.1.2.4. Hospital monitoring & evaluation system 
Table (4.12): Participant’s perception towards the current monitoring and 
evaluation system of the MoH 
 
Strongly 
Disagree 
Disagree Uncertain Agree 
Strongly 
Agree 
Mean 
Mean % of 
positive 
responses 
1- There is a monitoring system to measure physicians compliance with EDL 
No. 30 76 113 67 5 
2.8 56 
%  10.3 26.1 38.8 23.0 1.7 
2- There is a monitoring system to measure physicians compliance with protocols 
No. 23 74 121 65 11 
2.89 57.8 
%  7.8 25.2 41.2 22.1 3.7 
3- The current hospital monitoring system is efficient and effective 
No. 25 90 116 56 8 
2.77 55.4 
%  8.5 30.5 39.3 19.0 2.7 
4- There are performance indicators for protocol compliance in the hospitals 
No. 20 89 129 48 7 
2.77 55.4 
%  6.8 30.4 44.0 16.4 2.4 
5- You receive a feedback for protocol compliance 
No. 38 103 109 41 3 
2.55 51 
%  12.9 35.0 37.1 13.9 1.0 
6- Compliance with protocol affect your performance appraisal 
No. 23 87 126 51 5 
2.75 55 
%  7.9 29.8 43.2 17.5 1.7 
7- Audit directorate monitors drugs that you prescribe 
No. 18 79 133 45 7 
2.8 56 
%  6.4 28.0 47.2 16.0 2.5 
Mean%: 54.37%                            SD: 3.178 
 
 
As shown in the Table (4.12), there was a negative perception about the current hospital 
Monitoring and Evaluation system. The overall mean percentage of the study participant's 
perception about the current hospital Monitoring and Evaluation system was 54.37% (SD: 
3.178). As shown in the Table (4.12), the majority of the study participants (75.2%) were 
either uncertain or declined the existence of monitoring system in the MoH to measure 
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physicians compliance with EDL drugs. The mean percentage was 56%. Additionally, as 
shown in Table (4.12), 74.2% of the study participants were either uncertain or declined the 
presence of monitoring system to assess physicians compliance with the treatment protocols. 
The mean percentage was 57.8%. As shown in Table (4.12), the majority of the study 
participants (78.3%) were either uncertain or disagreed on the effectiveness of current hospital 
Monitoring and Evaluation system. The mean percentage was 55.4%. Furthermore, as shown 
in the Table (4.12), 81.2% of the study participants were either uncertain or disagreed on the 
existence of performance indicators on their compliance with the current treatment protocols. 
The mean percentage was 55.4%. Regarding the study participants perceptions about getting 
feedback on their compliance with the current treatment protocol, as shown in the Table 
(4.12), the majority of the study participants (85%) were either uncertain or did not receive 
feedback on their compliance with the current treatment protocols. The mean percentage was 
51%. Table (4.12) shows that the majority of the study participants (80.9%) were either 
uncertain or disagreed that their compliance with the treatment protocol affects the 
performance appraisal. The mean percentage was 55%. Finally, around half of the study 
participants (47.2%) were uncertain of the audit directorate monitoring roles in the hospitals. 
The mean percentage was 56%. This finding is consistent with Fattouh and Abu Hamad study 
(2010).  
4.1.3. Ministry of Health management 
This part highlights aspects related to the MoH management efforts to increase physician‘s 
compliance with EDL including managerial efforts and drug supply efforts.  
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4.1.3.1.  Actions related to EDL establishment and drug supplies 
Table (4.13): Participants knowledge about the EDL setting up process 
Variable  Al-Shifa Nasser EGH 
Kamal 
Odwan 
Al-Aqsa Total 
1- Participation in developing up  hospital or MoH-EDL 
MoH- EDL 
No. 5 0 1 1 0 7 
%  4.6% 0.0% 2.2% 3.2% 0.0% 2.4% 
Hospital EDL 
No. 11 2 1 2 3 19 
%  10.2% 2.9% 2.2% 6.5% 7.5% 6.5% 
Both EDLs 
No. 5 0 0 0 1 6 
%  4.6% 0.0% 0.0% 0.0% 2.5% 2.0% 
Did not participate 
in any  
No. 87 67 43 28 36 261 
%  80.6% 97.1% 95.6% 90.3% 90.0% 89.1% 
Total 
No. 108 69 45 31 40 293 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2- Having copy of MoH-EDL 
Paper 
No. 6 9 3 5 9 32 
%  5.6% 13.2% 6.7% 16.7% 22.5% 11.0% 
Electronic 
No. 5 2 0 0 0 7 
%  4.7% 2.9% 0.0% 0.0% 0.0% 2.4% 
Paper & Electronic 
No. 6 1 1 0 1 9 
%  5.6% 1.5% 2.2% 0.0% 2.5% 3.1% 
Do not have any 
copy 
No. 90 56 41 25 30 242 
%  84.1% 82.4% 91.1% 83.3% 75.0% 83.4% 
Total 
No. 107 68 45 30 40 290 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
With regard to the study participants involvement in the development of the MoH-EDL or 
hospitals EDL, Table (4.13) shows that the majority of the study participants (89.1%) neither 
participated in developing MoH-EDL, nor participated in developing hospital EDL. The 
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highest percentage of the study participants who neither participated in developing MoH-EDL 
nor participated in developing Hospital EDL was observed at Nasser hospital, as indicated by 
97.1% of the hospital participants. The lowest percentage of the study participants who neither 
participated in developing MoH-EDL nor participated in developing hospital EDL was 
observed at Al-Shifa hospital, as indicated by 80.6% of the hospital participants. This finding 
is consistent with Fattouh and Abu Hamad study (2010). As clearly appeared from the Table 
(4.13), the majority of the study participants (83.4%) indicated that they do not have hard or 
soft copies of MoH-EDL. The highest percentage of the study participants who indicated that 
they do not have hard or soft copies of MoH-EDL was observed at EGH hospital, as indicated 
by 91.1% of the hospital participants. The lowest percent of the study participants who 
indicated not having hard or soft copies of MoH-EDL was observed at Al-Aqsa hospital, as 
indicated by 75% of the hospital participants. This finding is inconsistent with Fattouh and 
Abu Hamad study (2010) as well as Mulwa and Colleagues study (2015).  
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Table (4.14): Participant’s awareness about the EDL selection criteria.  
 
Strongly 
Disagree 
Disagree Uncertain Agree 
Strongly 
Agree 
Mean 
Mean % of 
positive 
responses 
1- Patients opinion is important criteria for EDL selection 
No. 50 95 81 53 5 
3.65 73 
%  17.6 33.5 28.5 18.7 1.8 
2- Drug company influence is important criteria for EDL selection 
No. 31 91 72 74 20 
3.18 63.6 
%  10.8 31.6 25.0 25.7 6.9 
3- Political decisions are important criteria for EDL selection 
No. 41 78 102 54 12 
3.44 68.8 
%  14.3 27.2 35.5 18.8 4.2 
4- Drug cost is one of the EDL selection criteria 
No. 12 52 91 112 16 
3.24 64.8 
%  4.2 18.4 32.2 39.6 5.7 
5- Drug effectiveness is one of the EDL selection criteria 
No. 8 21 65 152 40 
3.68 73.6 
%  2.8 7.3 22.7 53.1 14.0 
6- Drug safety is one of the EDL selection criteria 
No. 4 14 71 156 41 
3.76 75.2 
%  1.4 4.9 24.8 54.5 14.3 
7- Drug quality is one of the EDL selection criteria 
No. 6 20 59 151 51 
3.77 75.4 
%  2.1 7.0 20.6 52.6 17.8 
8- Drug availability in the market is one of the EDL selection criteria 
No. 7 23 62 162 31 
3.66 73.2 
%  2.5 8.1 21.8 56.8 10.9 
9- One active ingredient per drug is one of the EDL selection criteria 
No. 9 46 115 92 20 
3.24 64.8 
%  3.2 16.3 40.8 32.6 7.1 
10- Country epidemiological profile is one of the EDL selection criteria 
No. 7 21 80 152 25 
3.59 71.8 
%  2.5 7.4 28.1 53.3 8.8 
Mean%: 72.84%                         SD: 9.498 
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Table (4.14) shows aspects of findings related to the study participant‘s knowledge about the 
EDL selection criteria. 
As shown in the Table (4.14), there was a good level of knowledge about the scientific 
selection criteria of the EDL, the overall mean percentage of the study participant's level of 
knowledge about EDL selection criteria was 72.84% (SD: 9.498). Table (4.14) shows that, 
only half of the study participants (51.1%) disagreed that the patient‘s opinion is an important 
EDL selection criterion. The mean percentage was 50.8%. As specified previously, it is well-
known that patient‘s opinion is not a scientific EDL selection criterion. As shown in Table 
(4.14), only 42.4% of the study participants disagreed that the pharmaceutical drug 
companies‘ influence could be included in the selection of EDL drugs. The mean percentage 
was 57.2%. As specified previously, it is well-known that pharmaceutical drug companies 
should not have an influence in the selection of EDL drugs. As shown in Table (4.14), 41.5% 
of the study participants disagreed that the political decisions are factors that could influence 
the selection of EDL drugs. The mean percentage was 54.2%. As specified previously, it is 
well-known that political decisions should not be considered in the selection of EDL drugs. As 
shown in the Table (4.14), 45.3% of the study participants agreed that the drug cost is an EDL 
selection criterion, while, 32.2% of the study participants were uncertain of that. The mean 
percentage was 64.8%. Generally, as specified previously, drug cost is one of the main factors 
in the selection of EDL drugs. Regarding the drug effectiveness as a selection criterion of EDL 
drugs, as shown in the Table (4.14), 67.1% of the study participants considered the drug 
effectiveness as an EDL selection criterion, while 22.7% of the study participants were 
uncertain of that. The mean percentage was 73.6%. As specified previously, it is well-known 
that drug effectiveness is a scientific EDL selection criterion. Moreover, as shown in the 
Table (4.14), around two thirds of the study participants (68.8%) considered the drug safety as 
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an EDL selection criterion while, 24.8% of the study participants were uncertain of that. The 
mean percentage was 75.2%. As specified previously, it is well-known that drug safety is a 
scientific EDL selection criterion. Additionally, more than two thirds of the study participants 
(70.4%) considered the drug quality as an EDL selection criterion while, 20.6% of the study 
participants were uncertain of that. The mean percentage was 75.4%. As specified previously, 
it is well-known that the drug quality is a scientific EDL selection criterion. Furthermore, as 
shown in the Table (4.14), around two thirds of the study participants (67.7%) considered the 
drug availability in the local market as an EDL selection criterion while, 21.8% of the study 
participants were uncertain of that. The mean percentage was 73.2%. As specified previously, 
it is well-known that the availability of drugs in the local market is a scientific EDL selection 
criterion. As shown in the Table (4.14), nearly one third of the study participants (39.7%) 
considered having one active ingredient per dosage form of drug as one of the selection 
criteria for EDL while, 40.8% of the study participants were uncertain of that. The mean 
percentage was 64.8%. As specified previously, it is well-known that one active ingredient per 
drug is a scientific EDL selection criterion. Finally, as shown in the Table (4.14), 62.1% of 
the study participants considered country epidemiological profile as an EDL selection 
criterion, while 28.1% of the study participants were uncertain of that. The mean percentage 
was 71.8%. As specified previously, it is well-known that country epidemiological profile is a 
scientific EDL selection criterion. This finding showed less knowledge of the study 
participants about the EDL selection criteria than that observed in the primary health care 
centers as showed by Fattouh and Abu Hamad study (2010) as well as Hettihawa and 
Jayarathna study (2010).  
The researcher believes that the level of knowledge of the study participants about the 
selection criteria of the EDL is inadequate and significant efforts must be made to increase 
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that level of knowledge. The main reason for this level of knowledge is the lack of 
implementation of training sessions for physicians as mentioned above. Additionally, this low 
level of knowledge about the selection criteria of the EDL can be attributed to the lack of 
activity conducted by the concerned entities in the MoH or ineffectiveness of its activities. 
4.1.3.2. Drug supply efforts 
 
This part reflects study participants knowledge about the Ministry of Health management 
efforts for drug supply.  
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Table (4.15): Participants knowledge about the available drugs in the hospitals 
Variable  Al-Shifa Nasser EGH 
Kamal 
Odwan 
Al-Aqsa Total 
1- EDL drugs are available at hospital pharmacy all the time 
Always 
No. 22 16 4 5 10 57 
%  20.2% 24.2% 9.1% 17.2% 25.0% 19.8% 
Rarely 
No. 76 47 34 21 27 205 
%  69.7% 71.2% 77.3% 72.4% 67.5% 71.2% 
Not Available 
No. 11 3 6 3 3 26 
%  10.1% 4.5% 13.6% 10.3% 7.5% 9.0% 
Total 
No. 109 66 44 29 40 288 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
2- Quantity of EDL drugs at hospital pharmacy are enough 
All Drugs 
No. 16 13 1 5 9 44 
%  14.8% 19.7% 2.3% 17.2% 22.5% 15.3% 
Some Drugs 
No. 88 52 42 24 30 236 
%  81.5% 78.8% 95.5% 82.8% 75.0% 82.2% 
None of The 
Drugs 
No. 4 1 1 0 1 7 
%  3.7% 1.5% 2.3% 0.0% 2.5% 2.4% 
Total 
No. 108 66 44 29 40 287 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
3- Drugs at the hospital pharmacy are of high quality   
Always 
No. 22 19 4 5 15 65 
%  20.2% 28.4% 9.1% 17.2% 37.5% 22.5% 
Rarely  
No. 71 44 36 20 19 190 
%  65.1% 65.7% 81.8% 69.0% 47.5% 65.7% 
Not 
No. 16 4 4 4 6 34 
%  14.7% 6.0% 9.1% 13.8% 15.0% 11.8% 
Total 
No. 109 67 44 29 40 289 
%  100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 
 
Regarding the study participants perception about the availability of EDL drugs at the study 
settings, as in shown the Table (4.15), only 19.8% of the study participants acknowledged that 
EDL drugs are available all the time in the hospital. The highest percentage of the study 
participants who informed that EDL drugs are available all the time in the hospital was 
observed at Al-Aqsa hospital, as indicated by 25% of the hospital participants. The lowest 
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percentage of the study participants who acknowledged that EDL drugs are available all the 
time in the hospital was observed at EGH hospital, as indicated by 9.1% of the hospital 
participants. 
The researcher believes that the continuous shortage of medications at the hospital pharmacies 
was due to: the political rift; the lack of capacity of the MoH in GG to supply all the required 
medicines; the destruction of the Rafah illegal tunnels; the closure of the Rafah border 
crossing which limited – and sometimes prevented – the humanitarian relief convoys from 
reaching GG. It was noted that the war in Syria had a significant impact in changing of donor 
trends and preferences to support Syria over Gaza because of the tragic situation there. All of 
the mentioned above led to extreme decline in the supply of medicine to the MoH warehouses 
Consequently, the central drug stores stocks declined quickly and the MoH became unable to 
support the stock at the appropriate time. 
With regard to the study participant‘s perception about the quantities of EDL drugs available 
at the hospital, as shown in the Table (4.15), only 15.3% of the study participants considered 
the quantities of all available drugs in the hospital are enough. The highest percent of the study 
participants who considered the quantities of all available drugs in the hospital enough was 
observed at Al-Aqsa hospital, as indicated by 22.5% of the hospital participants. The lowest 
percent of the study participants who considered the quantities of all available drugs in the 
hospital enough was observed at EGH hospital, as indicated by 2.3% of the hospital 
participants. 
With regard to the study participant‘s perception about the quality of EDL drugs available at 
the hospitals, as shown in the Table (4.15), only 22.5% of the study participants agreed that 
EDL drugs are of high quality all the time. The highest percent of the study participants who 
considered the EDL drugs of high quality all the time was observed at Al-Aqsa hospital, as 
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indicated by 37.5% of the hospital participants. The lowest percent of the study participants 
who considered the EDL drugs of high quality all the time was observed at EGH hospital, as 
indicated by 9.1% of the hospital participants. This finding showed low level of knowledge of 
the study participants about the quality of the available EDL drugs in comparison to the Indian 
study conducted by Gupta et al., (2015).  
 
This low level of perception of the study participant‘s about the quality of EDL drugs can be 
attributed to their lack of access to the necessary training about the EDL contents and concept, 
and also to lack of knowledge about the MoH quality control steps conducted to insure the 
quality and safety of medicines before releasing it to hospitals. Moreover, repeated complaints 
concerning the quality of EDL medicines in hospitals have been reported and some drugs have 
been stopped due to changes in their quality in a way that made them fail to meet the drug 
quality standards.   In addition, the low percent of physician‘s perception about the quality of 
EDL drugs can result from the fact that some of the EDL drugs came from donations. Such 
drugs have no quality guarantees since donations are not stored properly during transportation 
to GG. As a proof of the bad quality of some donations, the department of quality control at 
the general directorate of Pharmacy reported many complaints on the quality of these 
medicines and stopped dispensing many of it. Moreover, this low perception might be due to 
the adoption and implementation the shelf life extension program for medicines beyond their 
expiration date in the MoH central drug stores. Furthermore, the medical representative 
activities of pharmaceutical drug companies in marketing their innovative drugs through 
providing physicians with studies proving the weakness of conventional medicines (a lot of 
them are included in the EDL) compared to innovative medicines. 
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4.1.3.3. Monitoring and evaluation system 
Figure (4.7) reflects the relation between the MoH Monitoring and Evaluation directorate and 
the study participant‘s in terms of feedback about compliance with EDL drugs. 
 
 
The study findings showed that physicians had negative perception about the role of the MoH 
Monitoring and Evaluation directorate inside the hospitals to improve compliance with EDL. 
As shown in the Figure (4.7), the vast majority of the study participants (92.8%) have not 
received any feedback from the Monitoring and Evaluation directorate about their compliance 
with EDL. The highest percent of the study participants who have not received any feedback 
from the Monitoring and Evaluation directorate about their compliance with EDL was 
observed at EGH hospital, as indicated by 95.5% of the hospital participants. The lowest 
percentage of the study participants who have not received any feedback from the Monitoring 
and Evaluation directorate about their compliance with EDL was observed at Al-Shifa 
hospital, as indicated by 89.9% of the hospital participants.  
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Table (4.16): Participant’s attitude toward EDL drugs included in treatment 
protocols 
 
Strongly 
Disagree 
Disagree Uncertain Agree 
Strongly 
Agree 
Mean 
Mean % of 
positive 
responses 
1- Drugs included in the MoH treatment protocols are effective 
No. 10 58 91 126 6 
3.21 64.2 
%  3.4 19.9 31.3 43.3 2.1 
2- The current treatment protocols needs update 
No. 3 11 55 155 72 
3.95 79 
%  1.0 3.7 18.6 52.4 24.3 
3- The treatment protocols are obligatory for participants in the work 
No. 10 70 47 148 17 
3.32 66.4 
%  3.4 24.0 16.1 50.7 5.8 
4- Hospital pharmacy has a role in increasing compliance with  treatment protocols 
No. 10 54 81 134 17 
3.32 66.4 
%  3.4 18.2 27.4 45.3 5.7 
5- Compliance with treatment protocols reduce total health cost 
No. 7 22 70 169 24 
3.62 72.4 
%  2.4 7.5 24.0 57.9 8.2 
6- EDL drugs included in the treatment protocols are less effective than others 
No. 16 87 105 78 8 
2.91 58.2 
%  5.4 29.6 35.7 26.5 2.7 
Mean%: 60.47%                   SD: 2.841 
 
As shown in the Table (4.16), there was a mixture of perception components consisting of 
positive and negative ones toward the MoH treatment protocols and its contents of  EDL 
drugs, the overall mean percentage of the study participant's attitude about current protocols 
was 60.47% (SD:2.841). As shown in the Table (4.16), only 45.4% of the study participants 
considered the EDL drugs included in the current protocols effective. The mean percentage 
was 64.2%. Additionally, as shown in Table (4.16), the majority of the study participants 
(76.7%) agreed on the necessity for updating the current treatment protocols. The mean 
percentage was 79%. As shown in the Table (4.16), more than half of the study participants 
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(56.5%) perceived that the current treatment protocols are obligatory for them in the work. 
The mean percentage was 66.4%. Furthermore, as shown in the Table (4.16), nearly half of 
the study participants (51%) confirmed that the hospital pharmacy has a role in increasing 
their compliance with treatment protocols. The mean percentage was 66.4%. As shown in the 
Table (4.16), two thirds of the study participants (66.1%) agreed that the compliance with 
treatment protocols reduces the total health cost. The mean percentage was 72.4%. Finally, as 
shown in the Table (4.16), more than two thirds of the study participants (70.7%) were either 
uncertain or disagreed that EDL drugs included in the protocols are less effective than others. 
The mean percentage was 58.2%. 
The researcher sees that the study participants have a mixed perception components consisting 
of positive and negative ones toward the MoH treatment protocols and its contents of EDL 
drugs was expected due to many reasons: the absence of the process of updating these 
treatment protocols over the past years; the absence of the training program and awareness 
sessions; and the absence of the measuring indicators used to monitor physicians compliance.    
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4.2. Findings from in-patients medication sheet  
 
Out of the total number of collected 1098 in-patient medication sheets, 232 sheets (21.1%) 
were collected from Al-Shifa hospital, 204 sheets (18.6%) were collected from Nasser 
hospital, 210 sheets (19.1%) were collected from EGH hospital, 197 sheet (17.9%) were 
collected from Kamal Odwan hospital, and 255 sheets (23.2%) were collected from Al-Aqsa 
hospital. Figure (4.8) shows the distribution of in-patient medication sheets by hospitals. 
 
 
 
 
 
 
 
 
 
232 
204 210 197 
255 
0
50
100
150
200
250
300
Al-Shifa Nasser EGH Kamal Odwan Al-Aqsa
Figure (4.8) Total number of  in-patient medication sheets 
collected from hospitals 
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4.2.1. Descriptive analysis of in-patient medication sheet data 
Table (4.17) Descriptive findings related to the in-patient medication sheets 
Variable Hospital Mean 
Std. 
Deviation 
F value Sig. 
Total No. of 
prescribed 
drugs 
Al-Shifa 5.46 2.768   
Nasser 5.53 3.334   
EGH 5.26 3.381 2.738 0.028* 
Kamal Odwan 5.21 2.963   
Al-Aqsa 4.68 3.174   
Total 5.21 3.138   
No. of 
prescribed 
drugs from 
the EDL  
Al-Shifa 5.30 2.761   
Nasser 5.26 3.078   
EGH 5.14 3.323 2.70 0.029* 
Kamal Odwan 5.16 3.068   
Al-Aqsa 4.52 2.967   
Total 5.06 3.045   
No. of 
prescribed 
drugs out of 
the EDL  
Al-Shifa .32 .619   
Nasser .29 .597   
EGH .32 .655 0.643 0.632 
Kamal Odwan .24 .494   
Al-Aqsa .28 .619   
Total .29 .601   
No. of 
prescribed 
drugs using 
trade names 
Al-Shifa 4.37 2.298   
Nasser 2.47 2.322   
EGH 2.49 2.108 45.280 0.000* 
Kamal Odwan 4.04 2.451   
Al-Aqsa 2.21 2.064   
Total 3.10 2.418   
No. of 
prescribed 
drugs using 
scientific 
names 
Al-Shifa 1.25 1.301   
Nasser 3.09 2.168   
EGH 2.98 2.146 45.257 0.000* 
Kamal Odwan 1.36 1.455   
Al-Aqsa 2.59 2.307   
Total 2.25 2.081   
No. of 
prescribed 
drugs written 
in  English 
language 
Al-Shifa 5.20 3.015   
Nasser 5.51 3.309   
EGH 5.46 3.568 2.421 0.047* 
Kamal Odwan 5.11 2.990   
Al-Aqsa 4.70 3.165   
Total 5.18 3.221   
* Statistically significant  
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As shown in Table (4.17), the average total number of drugs prescribed in the in-patient 
medication sheet among the study settings was 5.21 drugs per sheet. The highest number of 
drugs prescribed was reported at Nasser hospital with an average of 5.53 drugs per sheet, 
while the lowest number of drugs prescribed was reported at Al-Aqsa hospital with an average 
of 4.68 drugs per sheet.  
One way Anova test was conducted to examine the presence of statistically significant 
differences among the study settings concerning the mean of the total number of drugs 
prescribed in the in-patient medication sheets. As shown in Table (4.17), there was a 
statistically significant difference in the mean of drugs prescribed in the in-patient medication 
sheet among the study settings with (F=2.738, P value=0.028). Post Hoc- Bonfirroni test has 
revealed a statistically significant difference between Nasser hospital and Al-Aqsa hospital 
(Sig. =0.038). It seems that physicians at Nasser hospital tend to prescribe more drugs in the 
in-patient medication sheet than physicians at Al-Aqsa hospital. This finding showed higher 
number of drugs prescribed at the study settings than that reported in several studies (Mariam 
et al., 2015;  Chedi et al., 2015; Ingle et al., 2015; Prasad et al., 2015; Afriyie et al., 2014; Akl 
et al., 2014; Ndukwe, 2013; Adibi et al., 2012). The higher number of prescribed drugs 
reported in the in-patient medication sheets in this study might be due to the multispecialty of 
the study settings. 
Concerning the No. of EDL drugs prescribed in the in-patient medication sheet, as shown in 
Table (4.17), the overall average number of drugs prescribed from the EDL among the study 
settings was 5.06 drugs per sheet. The highest number of drugs prescribed from the EDL was 
reported at Al-Shifa hospital with an average of 5.3 drugs per sheet, while the lowest number 
of drugs prescribed from the EDL was reported at Al-Aqsa hospital with an average of 4.52 
drugs per sheet. One way Anova test was conducted to examine the presence of statistically 
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significant differences among the study settings concerning the number of EDL listed drugs 
prescribed in the in-patient medication sheet. As shown in Table (4.17), there was a 
statistically significant difference in the mean number of EDL listed drugs prescribed in the in-
patient medication sheet among the study settings with (F=2.70, P value=0.029). Post Hoc - 
Bonfirroni test has revealed a statistically significant difference between Al-Shifa hospital and 
Al-Aqsa hospital (Sig. =0.047). It seems that physicians at Al-Shifa hospital tend to prescribe 
more drugs that are listed in the EDL in the in-patient medication sheet than physicians at Al-
Aqsa hospital. This finding seems to be logic when we know that all complicated cases at Al-
Aqsa hospital are referred to Al-Shifa medical complex. 
Figure (4.9) shows the percentage of physician‘s compliance with EDL in the in-patient 
medication sheet among the study settings. 
 
 
As shown in Figure (4.9), the majority of the collected in-patient medication sheets (78%) are 
fully compliant with EDL, which means that most the prescribed drugs in the in-patient 
medication sheets are from the EDL. Sheets that are partially compliant with EDL (contain 
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Figure (4.9) Physicians compliance with EDL in the in-
patient medication sheet 
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EDL and NEDL drugs prescribed in the same sheet) represent 22% of the total number of 
collected in-patient medication sheets. Sheets that are not compliant with EDL drugs at all 
represent less than 1% of the total collected in-patient medication sheets. This finding showed 
that the number of EDL drugs prescribed at the study settings was lower than that observed in 
several studies (Mariam et al., 2015;  Chedi et al., 2015; Prasad et al., 2015; Ndukwe, 2013), 
but higher than other studies (Ingle et al., 2015; Afriyie et al., 2014; Goel et al.,). This may be 
due to the multispecialty of the study settings. 
The researcher sees that the lack of commitment of physicians to prescribe EDL drugs can be 
attributed to several reasons, the most important are: not all drugs are available in the hospital; 
drugs are not available in sufficient quantities in the hospitals due to recurrent shortages ; 
some NEDL drugs are provided to the hospitals in the form of donations; the ineffectiveness 
of hospital pharmacists role in improving physicians compliance because of lack of 
pharmacists participation in the morning meetings ; lack of physicians knowledge about the 
alternative medications available at the hospital pharmacy; the present activities of  medical 
representatives of pharmaceutical drug companies inside hospitals; a lot of patients are 
chronically ill and receiving NEDL drugs before their admission to the hospital and it is not 
correct to change their medications into EDL drugs during their period of admission in the 
hospital which is probably the most important reason that led to the lack of commitment to 
prescribe EDL drugs  for admitted patients; and the absence of any role for the General 
Directorate of Monitoring and Evaluation in follow-up and documentation of this 
phenomenon. 
With regard to the No. of drugs prescribed out of the EDL (NEDL) in the in-patient 
medication sheets, as shown in Table (4.17), the average number of NEDL drugs prescribed 
in the in-patient medication sheets among the study settings was 0.29 drugs per sheet, the 
 87 
 
highest number of NEDL drugs prescribed was reported at both Al-Shifa and EGH hospitals 
with an average of 0.32 drugs per sheet, the lowest number of NEDL drugs prescribed was 
reported at Kamal Odwan hospital with an average of 0.24 drugs per sheet.  
One way Anova test was conducted to examine the presence of statistically significant 
differences among the study settings concerning the mean number of NEDL drugs prescribed 
in the in-patient medication sheets. As shown in Table (4.17), there was no statistically 
significant difference in the mean number of NEDL drugs prescribed in the in-patient 
medication sheets among the study settings with (F=0.643, P value=0.632). 
Concerning the No. of drugs prescribed using trade names in the in-patient medication sheets, 
as shown in Table (4.17), the average number of drugs prescribed by using trade names in the 
in-patient medication sheets among the study settings was 3.1 drugs per sheet. The highest 
number of drugs prescribed by using trade names was reported at Al-Shifa hospital with an 
average of 4.37 drugs per sheet, while the lowest number of drugs prescribed by using trade 
names was reported at Al-Aqsa hospital with an average of 2.21 drugs per sheet. One way 
Anova test was conducted to examine the presence of statistically significant differences 
among the study settings concerning the mean number of drugs prescribed by using trade 
names in the in-patient medication sheets. As shown in Table (4.17), there was a strong 
statistically significant difference in the mean of drugs prescribed by using trade names in the 
in-patient medication sheets among the study settings with (F=45.280, P value=0.000).Post 
Hoc - Bonfirroni test has revealed that the a significant difference was reported between Al-
Shifa hospital and the other three hospitals: Nasser hospital (Sig. = 0.000), EGH hospital (Sig. 
= 0.000), and Al-Aqsa hospital (Sig. = 0.000), clearly indicating that physicians at Al-Shifa 
hospital tend to prescribe more drugs by using trade names in the in-patient medication sheets 
than physicians at the other three hospitals.  
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Another significant difference was reported between Kamal Odwan hospital and three other 
hospitals: Nasser hospital (Sig. = 0.000), EGH hospital (Sig. = 0.000), and Al-Aqsa (Sig. = 
0.000), indicating that physicians at Kamal Odwan hospital tends to prescribe more drugs by 
using trade names in the in-patient medication sheets than physicians at the other three 
hospitals.  
With regard to the number of drugs prescribed using scientific names in the in-patient 
medication sheets, as shown in Table (4.17), the average number of drugs prescribed by using 
scientific names in the in-patient medication sheets among the study settings was 2.25 drugs 
per sheet. The highest number of drugs prescribed by using scientific names was reported at 
Nasser hospital with an average of 3.09 drugs per sheet, while the lowest number of drugs 
prescribed by using scientific names was reported at Al-Shifa hospital with an average of 1.25 
drugs per sheet.  
One way Anova test was conducted to examine the presence of statistically significant 
differences among the study settings concerning the mean number of drugs prescribed by 
using scientific names in the in-patient medication sheets. As shown in Table (4.17). The 
analysis revealed a strong statistically significant difference in the mean number of drugs 
prescribed by using scientific names in the in-patient medication sheets among the study 
settings with (F=45.257, P value=0.000). 
Figure (4.10) shows the percentage of physicians‘ compliance with scientific name 
prescribing of drugs in the in-patient medication sheet among the study settings 
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As shown in Figure (4.10), only 11% of the collected in-patient medication sheets were fully 
prescribed by scientific name (do not contain any drug prescribed by using trades names), 
which means that 11% of the collected in-patient medication sheets are fully compliant with 
prescribing drugs by using scientific names. Sheets that are partially compliant with 
prescribing drugs by using scientific names (contain drugs prescribed in scientific and trade 
names in the same sheet) represent 71% of the total number of collected in-patient medication 
sheets. Sheets that contain 100% of its drugs not prescribed using scientific names (prescribed 
using trade names only) represent 18% of the total number of collected in-patient medication 
sheets. 
The researcher believes that the lack of compliance of physicians to prescribe drugs by using 
scientific names results from: the lack of interest and support for this issue from the hospital 
management; the failure of the P&T Committee in promoting physicians prescribing by using 
scientific name of drug; the absence of indicators for measuring physicians compliance with 
prescribing by using scientific name; the failure of the hospital pharmacy to carry out its 
assigned role in improving physicians compliance through undesirable laxity in accepting and 
18% 
71% 
11% 
Figure (4.10) Physicians Compliance with scientific 
names of drugs in the in-patient medication sheets 
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 91 
 
dispensing requests prescribed by trade names of drugs; the absence of any role for the 
General Directorate of Monitoring and Evaluation in follow-up and documentation of this 
phenomenon. 
With regard to the number of drugs prescribed in English language in the in-patient 
medication sheets, as shown in Table (4.17), the average number of drugs prescribed in 
English language in the in-patient medication sheets among the study settings was 5.18 drugs 
per sheet. The highest number of drugs prescribed in English language was reported at Nasser 
hospital with an average of 5.51 drugs per sheet, while the lowest number of drugs prescribed 
in English language was reported at Al-Aqsa hospital with an average of 4.7 drugs per sheet. 
As shown in Table (4.17), the vast majority (96.5%) of the collected in-patient medication 
sheets were written in English language. One way Anova test was conducted to examine the 
presence of statistically significant differences among the study settings concerning the mean 
number of drugs prescribed in English language in the in-patient medication sheets. As shown 
in Table (4.17), there was a statistically significant difference in the mean of drugs prescribed 
in English language in the in-patient medication sheets among the study settings with 
(F=2.421, P value=0.047). 
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4.3.  Findings from emergency department reports  
Out of the total number of collected 1595 emergency department reports (EDRs), 386 reports 
(24.2%) were collected from Al-Shifa hospital, 289 reports (18.1%) were collected from 
Nasser hospital, 238 reports (14.9%) were collected from EGH hospital, 348 reports (21.8%) 
were collected from Kamal Odwan hospital, and 334 reports (20.9%) were collected from Al-
Aqsa hospital. Figure (4.11) shows the distribution of EDRs by hospitals. 
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Figure (4.11) Total number of ED reports collected from 
hospitals 
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4.3.1. Descriptive analysis of the emergency department reports 
Table (4.18) descriptive findings related to the emergency department reports 
Variable Hospital Mean 
Std. 
Deviation 
F value Sig. 
Total No. of 
prescribed 
drugs 
Al-Shifa 2.03 .815   
Nasser 2.22 .753   
EGH 2.11 .740 7.605 0.000* 
Kamal  Odwan 2.17 .718   
Al-Aqsa 2.33 .767   
Total 2.17 .769   
No. of 
prescribed 
drugs from the 
EDL  
Al-Shifa 0.97 .815   
Nasser 1.06 .840   
EGH 1.48 .967 14.951 0.000* 
Kamal  Odwan 1.12 .880   
Al-Aqsa 1.01 .856   
Total 1.10 .881   
No. of 
prescribed 
drugs out of 
the EDL  
Al-Shifa 1.06 .927   
Nasser 1.16 .857   
EGH 0.63 .773 22.047 0.000* 
Kamal  Odwan 1.05 .927   
Al-Aqsa 1.32 .891   
Total 1.07 .908   
No. of 
prescribed 
drugs using 
trade names 
Al-Shifa 1.91 .866   
Nasser 2.13 .766   
EGH 1.93 .809 9.026 0.000* 
Kamal  Odwan 2.09 .795   
Al-Aqsa 2.22 .778   
Total 2.06 .814   
No. of 
prescribed 
drugs using 
scientific 
names 
Al-Shifa .12 .346   
Nasser .09 .282   
EGH .18 .417 4.008 0.003* 
Kamal  Odwan .08 .278   
Al-Aqsa .10 .352   
Total .11 .336   
No. of 
prescribed 
drugs written 
in  English 
language 
Al-Shifa 2.03 .815   
Nasser 2.22 .753   
EGH 2.10 .756 7.396 0.000* 
Kamal  Odwan 2.16 .728   
Al-Aqsa 2.33 .770   
Total 2.17 .773   
* Statistically significant  
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As shown in Table (4.18), the average total number of drugs prescribed in the ED reports 
among the study settings was 2.17 drugs per ED report. The highest number of drugs 
prescribed was reported at Al-Aqsa hospital with an average of 2.33 drugs per ED report, 
while the lowest number of drugs prescribed was reported at Al-Shifa hospital with an average 
of 2.03 drugs per ED report. One way Anova test was conducted to examine the presence of 
statistically significant differences among the study settings concerning the mean of the total 
number of drugs prescribed in the ED reports. As shown in Table (4.18), there was a 
statistically significant difference in the mean number of drugs prescribed in the ED reports 
among the study settings with (F=7.605, P value=0.000). Post Hoc - Bonfirroni test has 
revealed that the significant difference was reported between Al-Shifa hospital and both 
Nasser hospital (Sig. =0.017) and Al-Aqsa hospital (Sig. =0.000). It seems that physicians at 
Al-Shifa hospital tend to prescribe fewer drugs in the ED reports than physicians at the other 
two hospitals. Another significant difference was reported between EGH and Al-Aqsa 
hospitals (Sig. =0.007). It seems that physicians at Al-Aqsa hospital tend to prescribe more 
drugs in the ED reports than EGH physicians. Concerning the No. of EDL drugs prescribed in 
the EDRs, as shown in Table (4.18), the overall average number of drugs prescribed from the 
EDL among the study settings was 1.1 drugs per ED report. The highest number of drugs 
prescribed from the EDL was reported at EGH hospital with an average of 1.48 drugs per ED 
report, while the lowest number of drugs prescribed from the EDL was reported at Al- Shifa 
hospital with an average of about one drug per ED report. One way Anova test was conducted 
to examine the presence of statistically significant differences among the study settings 
concerning the mean number of EDL listed drugs prescribed in the ED reports. As shown in 
Table (4.18), there was a strong statistically significant difference in the mean number of the 
drugs prescribed from the EDL in the ED reports among the study settings with (F=14.951, P 
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value=0.000). Post Hoc - Bonfirroni test- has revealed that the significant difference was 
reported between EGH hospital and all other four hospitals, clearly indicating that physicians 
at EGH hospital tend to prescribe more drugs that are listed in EDL in the ED reports than 
physicians at others four hospitals.  
Figure (4.12) shows the percentage of physician‘s compliance with EDL in the ED reports 
among the study settings. 
 
 As shown in Figure (4.12), only one third of the collected ED reports (31%) are fully 
compliant with EDL, which means that all the prescribed drugs are from the EDL. Reports 
those contain EDL and NEDL drugs in the same time represent 41% of the total number of 
collected ED reports, and reports those contain NEDL drugs and do not contain any EDL 
drugs represent 28% of the total number of collected ED reports, which means that around one 
third of the collected reports are not compliant with prescribing EDL drugs in the ED reports 
at all. 
With regard to the No. of drugs prescribed out of the EDL (NEDL) in the EDRs, as shown in 
Table (4.18), the average number of NEDL drugs prescribed in the ED reports among the 
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study settings was 1.07 drugs per ED report. The highest number of NEDL drugs prescribed 
was reported at Al-Aqsa hospital with an average of 1.32 drugs per ED report, while the 
lowest number of NEDL drugs prescribed was reported at EGH hospital with an average of 
0.63 drugs per ED report. One way Anova test was conducted to examine the presence of 
statistically significant differences among the study settings concerning the mean number 
NEDL drugs prescribed in the ED reports. As shown in Table (4.18), there was a strong 
statistically significant difference in the mean number of  NEDL drugs prescribed in the ED 
reports among the study settings with (F=22.047, P value=0.000).  
The researcher sees that the low level of compliance of physicians to prescribe EDL drugs in 
the EDRs is most likely due to several reasons, the most important are: not working of the out-
patient pharmacy in the evening and night duty time. Accordingly, it is not possible to 
dispense prescriptions issued in the emergency departments of these hospitals from the 
hospital pharmacy, whereas it can be dispensed from the primary health care center 
pharmacies or from private pharmacies only; the absence of any role for the hospital 
management in the follow-up process of physicians prescribing practice in the emergency 
departments ; the absence of any role for the hospital pharmacist in the follow-up of 
prescriptions issued by the physicians in the emergency departments; the frequent presence of 
medical representative of pharmaceutical drug companies at the emergency departments; and 
the absence of any role for the General Directorate of Monitoring and Evaluation in follow-up 
and documentation of this phenomenon in the emergency departments. Concerning the No. of 
drugs prescribed using trade names in the EDRs, as shown in Table (4.18), the average 
number of drugs prescribed by using trade names in the ED reports among the study settings 
was 2.06 drugs per ED report. The highest number of drugs prescribed using trade names was 
reported at Al-Aqsa hospital with an average of 2.22 drugs per ED report, while the lowest 
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number of drugs prescribed using trade names was reported at Al-Shifa hospital with an 
average of 1.91 drugs per ED report. One way Anova test was conducted to examine the 
presence of statistically significant differences among the study settings concerning the mean 
number of drugs prescribed by using trade names in the ED reports. As shown in Table (4.18), 
there was a strong statistically significant difference in the mean number of drugs prescribed 
by using trade names in the ED reports among the study settings with (F=9.026, P 
value=0.000).  Post Hoc - Bonfirroni test has revealed that the significant difference was 
between Al-Shifa hospital and three other hospitals: Nasser hospital (Sig. =0.003), Kamal 
Odwan hospital (Sig. =0.019), and Al-Aqsa hospital (Sig. =0.000), clearly indicating that 
physicians at Al-Shifa hospital tend to prescribe less drugs using trade names in the ED 
reports than physicians at the other three mentioned hospitals. Another significant difference 
was between EGH hospital and both Nasser (Sig. =0.049) and Al-Aqsa (Sig. =0.000) hospital, 
it seems that physicians at EGH hospital tend to prescribe less drugs by using trade names in 
the ED reports than physicians at the others two hospitals.  
With regard to the number of drugs prescribed using scientific names in the EDRs, as shown 
in Table (4.18), the average number of drugs prescribed using scientific names in the ED 
reports among the study settings was 0.11 drugs per ED report. The highest number of drugs 
prescribed using scientific names was reported at Al-Shifa hospital with an average of 0.12 
drugs per ED report, while the lowest number of drugs prescribed using scientific names was 
reported at Kamal Odwan hospital with an average of 0.08 drug per ED report. One way 
Anova test was conducted to examine the presence of statistically significant differences 
among the study settings concerning the mean number of drugs prescribed by using scientific 
names in the ED reports. As shown in Table (4.18), the analysis revealed a strong statistically 
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significant difference in the mean number of drugs prescribed by using scientific names in the 
ED reports among the study settings with (F=4.008, P value=0.003). 
Figure (4.13) shows the percentage of physician‘s compliance with scientific name 
prescribing of drugs in the ED reports among the study settings. 
 
 
As shown in Figure (4.13), the majority of the collected ED reports (89%) were fully 
prescribed using trade names, which means that 89% of the collected ED reports are not 
compliant with prescribing drugs by using scientific names at all. Reports that contain drugs 
prescribed using scientific and trade manes in the same time represent 9% of the total number 
of collected ED reports. ED reports that are not containing any drugs prescribed by using trade 
names at all represent 2% of the total collected ED reports, which means that physicians are 
poorly compliant with prescribing drugs by using scientific names in the ED reports.  
The researcher sees that the low level of compliance of physicians to prescribe drugs by using 
scientific names in the  ED reports is most likely due to several reasons, the most important 
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are: not working of the out-patient pharmacy in the evening and night duty time as mentioned 
above; the absence of any role for the hospital management in the follow-up process of 
physicians prescribing practice at the emergency departments; the absence of any role for the 
hospital pharmacist in the follow-up of prescriptions issued by the physicians in the 
emergency departments; the frequent presence of medical representative of pharmaceutical 
drug companies at the emergency departments; the absence of any role for the General 
Directorate of Monitoring and Evaluation in the follow-up and documentation of this 
phenomenon in the emergency departments; the absence of any measuring indicators to 
monitor the physicians practice; and the absence of any role for the hospital P&T committee in 
the measurement and management of this issue. 
With regard to the number of drugs prescribed in English language in the ED reports, as 
shown in Table (4.18), the average number of drugs prescribed in English language in the ED 
reports among the study settings was 2.17 drugs per ED report. The highest number of drugs 
prescribed in English language was reported at Al-Aqsa hospital with an average of 2.33 drugs 
per ED report, while the lowest number of drugs prescribed in English language was reported 
at Al-Shifa hospital with an average of 2.03 drugs per ED report. As shown in Table (4.18), 
the vast majority (99.6%) of the collected ED report were written in English language, which 
means that physicians are strongly compliant with prescribing drugs by using English 
language in the ED reports. One way Anova test was conducted to examine the presence of 
statistically significant differences among the study settings concerning the mean number of 
drugs prescribed in English language in the ED reports. As shown in Table (4.18), there was a 
strong statistically significant difference in the mean number of drugs prescribed in English 
language in the ED reports among the study settings with (F=7.396, P value=0.000). Post Hoc 
- Bonfirroni test revealed that the significant difference was between Al-Aqsa hospital and 
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both Al-Shifa (Sig. =0.000) and EGH hospital (Sig. =0.005), clearly indicating that physicians 
at Al-Aqsa hospital tend to prescribe more drugs in English language in the ED reports than 
physicians at the others two mentioned hospitals. Another significant difference was reported 
between Al-Shifa hospital and Nasser hospital (Sig. =0.018), clearly indicating that physicians 
at Nasser hospital tend to prescribe drugs in English language in the ED reports more than 
physicians at Al-Shifa hospital.  
It is worth mentioning that the average number of drugs prescribed in Arabic language in the 
ED reports among the study settings was almost zero drug per ED report.  
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4.4. Findings from in-patients discharge reports  
Out of the total number of collected 1226 in-patient discharge reports (IPDRs), 318 IPDRs 
(25.9%) were collected from Al-Shifa hospital, 231 IPDRs (18.8%) were collected from 
Nasser hospital, 223 IPDRs (18.2%) were collected from EGH hospital, 201 IPDRs (16.4%) 
were collected from Kamal Odwan hospital, and 253 IPDRs (20.6%) were collected from Al-
Aqsa hospital. Figure (4.14) shows the distribution of IPDRs by hospitals. 
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Figure (4.14) Total number of IPDRs collected from 
the study settings 
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4.4.1. Descriptive analysis of the in-patients discharge reports 
Table (4.19) descriptive findings related to the in-patient discharge reports 
 Hospital Mean 
Std. 
Deviation 
F value Sig. 
Total No. of 
prescribed 
drugs 
Al-Shifa 3.09 1.603   
Nasser 2.97 1.663   
EGH 2.85 1.850 1.186 0.315 
Kamal Odwan 3.14 1.698   
Al-Aqsa 2.92 1.720   
Total 3.00 1.701   
No. of 
prescribed 
drugs from 
the EDL  
Al-Shifa 1.87 1.649   
Nasser 1.71 1.698   
EGH 2.10 1.901 3.277 0.011* 
Kamal Odwan 2.24 1.701   
Al-Aqsa 1.86 1.681   
Total 1.94 1.728   
No. of 
prescribed 
drugs out of  
the EDL  
Al-Shifa 1.22 .984   
Nasser 1.25 .940   
EGH .75 .777 12.839 0.000* 
Kamal Odwan .91 .864   
Al-Aqsa 1.07 .967   
Total 1.06 .936   
No. of 
prescribed 
drugs using 
trade names 
Al-Shifa 2.71 1.333   
Nasser 2.56 1.287   
EGH 2.14 1.355 6.611 0.000* 
Kamal Odwan 2.69 1.306   
Al-Aqsa 2.53 1.487   
Total 2.54 1.370   
No. of 
prescribed 
drugs using 
scientific 
names 
Al-Shifa .38 .747   
Nasser .41 .812   
EGH .71 1.082 6.533 0.000* 
Kamal Odwan .46 .836   
Al-Aqsa .38 .677   
Total .46 .839   
No. of 
prescribed 
drugs written 
in  English 
language 
Al-Shifa 2.81 1.622   
Nasser 2.97 1.663   
EGH 2.85 1.850 1.328 0.257 
Kamal Odwan 3.14 1.698   
Al-Aqsa 2.89 1.688   
Total 2.92 1.700   
* Statistically significant  
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As shown in Table (4.19), the average total number of drugs prescribed in the IPDRs among 
the study settings was 3 drugs per IPD report. The highest number of drugs prescribed was 
reported at Kamal Odwan hospital with an average of 3.14 drugs per IPD report, while the 
lowest number of drugs prescribed was reported at EGH hospital with an average of 2.85 
drugs per IPD report.  
One way Anova test was conducted to examine the presence of statistically significant 
differences among the study settings concerning the mean of the total number of drugs 
prescribed in the IPDRs. As shown in Table (4.19), there was no statistically significant 
difference in the mean number of drugs prescribed in the IPDRs among the study settings with 
(F=1.186, P value=0.315).  
Concerning the No. of drugs prescribed from the EDL in the IPDRs, as shown in Table (4.19), 
the overall average number of drugs prescribed from the EDL in the IPDRs among the study 
settings was 1.94 drugs per IPD report. The highest number of drugs prescribed from the EDL 
was reported at Kamal Odwan hospital with an average of 2.24 drugs per IPD report, while the 
lowest number of drugs prescribed was reported at Nasser hospital with an average of 1.71 
drugs per IPD report. One way Anova test was conducted to examine the presence of 
statistically significant differences among the study settings concerning the mean number of 
EDL listed drugs prescribed in the IPDRs. As shown in Table (4.19), there was a statistically 
significant difference in the mean number of EDL listed drugs prescribed in the IPDRs among 
the study settings with (F=3.277, P value=0.011). Post Hoc – Bonfirroni- test has revealed that 
the significant difference was reported between Nasser hospital and Kamal Odwan hospital 
(Sig. =0.016). This finding clearly indicates that physicians at Kamal Odwan hospital tend to 
prescribe more drugs that are listed in the EDL in the IPDRs than physicians at Nasser 
hospital.  
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Figure (4.15) shows the percentage of physician‘s compliance with EDL in the IPDRs among 
the study settings. 
 
 
  As shown in Figure (4.15), nearly one third of the collected IPDRs (31%) are fully compliant 
with EDL, which means that all the prescribed drugs in the IPDRs are from the EDL. Reports 
those are partially compliant with EDL (contain EDL and NEDL drugs prescribed in the same 
report) represent 53% of the total number of collected IPDRs. Reports that are not compliant 
with EDL drugs at all represent 16% of the total collected IPDRs, which means that all the 
prescribed drugs in the IPDRs are out of the EDL. The researcher believes that the low level of 
compliance of physicians to prescribe EDL drugs in the IPDRs is most likely due to several 
reasons, the most important are: the limited role of the hospital management in the follow-up 
process of physicians prescribing practice; the limited role of the hospital pharmacist in the 
follow-up for drugs prescribed on the IPDRs issued by the physicians; the frequent presence of 
medical representative of pharmaceutical drug companies at the wards and physicians‘ offices; 
16% 
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Figure (4.15) Physicians compliance with EDL in the IPDRs 
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the limited role of the General Directorate of Monitoring and Evaluation in the follow-up and 
documentation of this phenomenon in the wards; the limited role of the hospital P&T 
committee in  managing this issue.  
 
With regard to the No. of drugs prescribed out of the EDL (NEDL) in the IPDRs, as shown in 
Table (4.19), the average number of NEDL drugs prescribed in the IPDRs among the study 
settings was 1.06 drugs per IPD report. The highest number of NEDL drugs prescribed in the 
IPDRs was reported at Nasser hospital with an average of 1.25 drugs per IPD report, while the 
lowest number of NEDL drugs prescribed in the IPDRs was reported at EGH hospital with an 
average of 0.75 drug per IPD report. One way Anova test was conducted to examine the 
presence of statistically significant differences among the study setting concerning the mean 
number of NEDL drugs prescribed in the IPDRs. As shown in Table (4.19), there was a strong 
statistically significant difference in the mean number of NEDL drugs prescribed in the IPDRs 
among the study settings with (F=12.839, P value=0.000). 
Concerning the No. of drugs prescribed using trade names in the IPDRs, as shown in Table 
(4.19), the average number of drugs prescribed by using trade names in the IPDRs among the 
study settings was 2.54 drugs per IPD report. The highest number of drugs prescribed by using 
trade names was reported at Al-Shifa hospital with an average of 2.71 drugs per IPD report, 
while the lowest number of drugs prescribed by using trade names was reported at EGH 
hospital with an average of 2.14 drugs per IPD report. One way Anova test was used to 
examine the presence of statistically significant differences among the study settings 
concerning the mean number of drugs prescribed by using trade names in the IPDRs. As 
shown in Table (4.19), there was a statistically significant difference in the mean number of 
drugs prescribed by using trade names in the IPDRs among the study settings with (F=6.611, P 
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value=0.000). Post Hoc - Bonfirroni test has revealed a statistically significant difference 
between EGH hospital and the other four hospitals: Al-Shifa hospital (Sig. = 0.000), Nasser 
hospital (Sig. = 0.012), Kamal Odwan hospital (Sig. = 0.000), and Al-Aqsa hospital (Sig. = 
0.018), clearly indicating that physicians at EGH hospital tend to prescribe less drugs by using 
trade names in the IPDRs than physicians at the other four hospitals.  
 
With regard to the number of drugs prescribed using scientific names in the IPDRs, as shown 
in Table (4.19), the average number of drugs prescribed by using scientific names in the 
IPDRs among the study setting was 0.46 drugs per IPD report. The highest number of drugs 
prescribed by using scientific names was reported at EGH hospital with an average of 0.71 
drugs per IPD report, while the lowest number of drugs prescribed by using scientific names 
was reported at both Al-Shifa and Al-Aqsa hospitals with an average of 0.38 drugs per IPD 
report. One way Anova test was conducted to examine the presence of statistically significant 
differences among the study settings concerning the mean number of drugs prescribed by 
using scientific names in the IPDRs. As shown in Table (4.19). The analysis revealed a 
statistically significant difference in the mean number of prescribed drugs prescribed by using 
scientific names in the IPDRs among the study settings with (F=6.533, P value=0.000). 
Figure (4.16) shows the percentage of physicians‘ compliance with scientific name 
prescribing of drugs in the IPDRs among the study settings. 
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As shown in Figure (4.16), the majority of the collected IPDRs (69%) were fully prescribed 
by trade names (do not contain any drug prescribed by using scientific names), which means 
that 69% of the collected IPDRs are not compliant with prescribing drugs by using scientific 
names at all. Reports that are partially compliant with prescribing drugs by using scientific 
names (contain drugs prescribed in scientific and trade names in the same report) represent 
29% of the total number of collected IPDRs. Reports that contain 100% of its drugs prescribed 
using scientific names represent 2% of the total number of collected IPDRs, which means that 
full physician‘s compliance with scientific name prescribing of drugs in the IPDRs represent 
only 2% of the collected IPDRs. With regard to the number of prescribed drugs prescribed in 
English language in the IPDRs, as shown in Table (4.19), the average number of drugs 
prescribed in English language in the IPDRs among the study settings was 2.92 drugs per IPD 
report. The highest number of drugs prescribed in English language was reported at Kamal 
Odwan hospital with an average of 3.14 drugs per IPD report, while the lowest number of 
drugs prescribed in English language was reported at Al-Shifa hospital with an average of 2.81 
69% 
29% 
2% 
Figure (4.16) Physicians Compliance with scientific Names of 
drugs in IPDRs 
No Compliance
Partial Compliance
100% Compliance
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drugs per IPD report. As shown in Table (4.19), the vast majority (98.1%) of the collected 
IPDRs were written in English language. One way Anova test was conducted to examine the 
presence of statistically significant differences among the study settings concerning the mean 
number of drugs prescribed in English language in the IPDRs. As shown in Table (4.19), there 
was no statistically significant difference in the mean number of drugs prescribed in English 
language in the IPDRs among the study settings with (F=1.328, P value=0.257). With regard 
to the number of drugs prescribed in Arabic language in the IPDRs, as shown in Table (4.19), 
the average number of drugs prescribed in Arabic language in the IPDRs among the study 
settings was 0.08 drugs per IPD report. The highest number of drugs prescribed in Arabic 
language was reported at Al-Shifa hospital with an average of 0.28 drugs per IPD report, while 
the lowest number of drugs prescribed in Arabic language was reported at EGH, Nasser, and 
Kamal Odwan hospitals with an average of zero drugs per IPDRs. One way Anova test was 
conducted to examine the presence of statistically significant differences among the study 
settings concerning the mean number of drugs prescribed in Arabic language in the IPDRs. As 
shown in Table (4.19), there was a statistically significant difference in the mean number of 
drugs prescribed in Arabic language in the IPDRs among the study settings with (F=11.190, P 
value=0.000). 
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Chapter (5) 
Conclusion and recommendations 
5.1. Conclusion 
Within the context of the Gaza Governorates, this study aimed to assess physicians‘ 
compliance with EDL at governmental hospitals. The findings of the study have shown that 
more than half of the study participants had private work in addition to their work in the MoH. 
The findings of the study have shown that knowledge of the study participants about the MoH-
EDL, hospital EDL and its updating process is not high. However, there is a positive attitude 
among physicians about the EDL and it benefits. The majority of the study participants agreed 
on the importance and necessity of EDL for: provision of equitable health services; provision 
of quality health services; reduction of wasting in financial resources; reducing patient harm; 
and the fact that the listed drugs in the EDL are selected on scientific bases. The majority of 
the study participants neither communicated with hospital pharmacists properly nor responded 
to pharmacists‘ recommendations in prescribing drugs from EDL. The study findings revealed 
that hospital management does not efficiently exercising its role in encouraging physicians to 
be compliant with EDL. For example, the hospitals managements in the study settings did not 
organized EDL awareness and training sessions to encourage physicians to prescribe EDL 
drugs. additionally, the study findings have shown that the majority of the study participants 
did not received any hospital EDL updates (neither hard nor soft EDL copies), indicating that 
there is communication gap between the study participants and both the MoH management 
and hospital management in the field of disseminating MoH-EDL updates. The poor 
communication issue can clearly be seen by looking at the results showing that only one third 
of the study participants were knowledgeable about the presence of treatment protocols in the 
hospital. According to the study participants, there was no adequate knowledge of physicians 
 119 
 
about the Hospital Pharmacy & Therapeutics committee. Moreover, the study revealed that, 
more than half of the study participants do not receive any treatment protocols from the 
Hospital P&T committee. Additionally, majority of the study participants have not received 
any feedback from the Hospital P&T committee related to compliance with EDL. According 
to the study participants, the hospital pharmacists neither inform nor update physicians 
adequately about the available drugs in the hospital, indicating that the hospital pharmacists 
are not doing their assigned role in encouraging physicians adequately to prescribe EDL drugs. 
This point need to be further investigated from the pharmacists working in the study settings. 
There is a negative perception about the effectiveness of the current hospital Monitoring and 
Evaluation system, as the majority of the study participants were either uncertain or even 
declined the existence of monitoring system in the hospital to measure physicians compliance 
with EDL drugs and treatment protocols. Most of the study participants have not received 
feedback on their compliance with the current treatment protocols. There is a good level of 
knowledge about the scientific selection criteria of the EDL. The majority of the study 
participants considered the quantities of all available drugs in the hospital are not enough. 
While, only one quarter of the study participants agreed that EDL drugs are of high quality all 
the time. The study showed that there was a mixture of perception components consisting of 
positive and negative ones towards the MoH treatment protocols and its contents of EDL 
drugs.  
The findings of the study have shown that the vast majority of the collected in-patient 
medication sheets are fully compliant with prescribing EDL drugs.  Moreover, the vast 
majority of the collected in-patient medication sheets were written in English language but 
low level compliance of prescribing drugs by using scientific names was noticed.  
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5.2. Recommendations 
5.2.1. MoH level 
1- MoH needs to implement a continuous education and training programs for healthcare staff 
concerning EDL and treatment protocols. MoH needs to identify training priority areas that 
physicians need to attain during their work.  
2- As the number of hard copies of the MoH EDL is insufficient, MoH needs to disseminate 
printed and softcopies copies of the EDL and hospital EDL. 
3- MoH has to activate the monitoring role of auditing system to improve physicians‘ 
compliance with EDL. 
4- There is a need to update the MoH EDL and hospital EDL. If MoH decides to update the 
EDL, it is important to involve more physicians in the updating process.   
5- There is a need to incorporate items related to the physicians‘ compliance with EDL and 
treatment protocols in the annual performance appraisal. 
6- There is a need to improve the communication among health care providers and establish 
measuring indicators for this communication.  
7- MoH needs to strengthen the role of the Central Pharmacy and Therapeutics committees. 
8- MoH needs to improve the role of Monitoring and Evaluation directorate to improve 
compliance to EDL.  
5.2.2. General directorate of pharmacy level 
1- The General Directorate of pharmacy has to establish regulations for revising the 
promotional materials used by medical representatives in the promotional activities to assure 
their scientific credibility and value and being unbiased source of information.   
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2- The General Directorate of pharmacy has to implement an awareness programs about the 
shelf life extension program for expired drug and quality control procedures for received 
medications in the central drug stores for all health staff. 
5.2.3. Learning institutions level 
1- Academic institutions and universities have to incorporate topics related to the EDL 
concepts in the curriculum of health related faculties. 
2- Academic institutions and universities have to incorporate topics related to quality, 
management, and communication skills in the curriculum of health related faculties. 
5.2.4. Recommendations for further research 
1- Conduct more research including both qualitative and quantitative methods to deeply 
understand hidden factors that might affect physicians‘ compliance with EDL 
2- Conduct research including both qualitative and quantitative methods for specialized 
governmental hospitals and private hospitals in the GG to assess the physicians‘ compliance. 
3- Conduct comparative studies to compare the physicians‘ compliance in the GG 
governmental hospitals with that in the West Bank governmental hospitals. 
4- Conduct comparative studies to compare the physicians‘ compliance in the NGOs and 
private hospitals with that in the governmental hospitals. 
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Annex (1): Palestine state map 
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Annex (2): Gaza Governorates map 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
http://www.wafainfo.ps/pics/GazaStrip 
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Annex (3): The governmental hospitals in GG. 
N0. Hospital name Location Bed capacity 
1 Al-Shifa Medical complex Middle of Gaza city 619 
2 Nasser Medical complex Middle of Khan Younis city 322 
3 European Gaza Hospital East of Khan Younis city 246 
4 Al-Aqsa Martyrs Hospital Middle of Deir Albalah city 129 
5 Al-Naser Pediatrics Hospital West of Gaza city 132 
6 Mohammed Al Najjar Hospital Middle of Rafah city 80 
7 Kamal Odwan Hospital Middle of Beit lahya city 119 
8 Beit Hanon Hospital Middle of Beit Hanon city 45 
9 Mohammed Al Dorrah hospital East of Gaza city 91 
10 Ophthalmic Hospital Middle of Gaza city 40 
11 Al-Helal Al-Emaraty Hospital West of Rafah city 52 
12 Abdelaziz Al Rantisi Hospital West of Gaza city 55 
Table number 2: the governmental hospitals in GG (Source: MoH, 2013) 
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Annex (4): The study settings 
Al-Shifa medical complex 
 Al Shifa medical complex was established in the year 1946 on an area of 42 thousand 
meter squares. It is located in the western side of Gaza City. Al Shifa Medical complex 
consists of four hospitals with different medical specialties including medical, surgical, and 
Obstetric and genecology services with a total beds capacity of 619 beds. In 2013, the total 
number of admitted cases was 62046 cases; bed occupancy rate was 107%, bed residency rate 
was 2.9 days (MoH, 2013). 
Al-Aqsa hospital 
 Al Aqsa Hospital was established in 2001 on an area of 4 thousand meter squares. It is 
located in the middle side of Deir El balah City. Al Aqsa hospital provides different medical 
specialties including medical, surgical and Obstetric and genecology services with a total beds 
capacity of 129 beds. In 2013, the total number of admitted cases was 15053 cases; bed 
occupancy rate was 79%, bed residency rate was 4.7days (MoH, 2013). 
Nasser medical complex 
 Nasser medical complex was established in 1960 on an area of 18.4 thousand meter 
squares; it is located in the western side of Khan Yonis City. Nasser Medical complex consists 
of three hospitals with different medical specialties including medical, surgical, and Obstetric 
and genecology services with a total beds capacity of 322 beds. In 2013, the total number of 
admitted cases was 32428 cases; bed occupancy rate was 80.4%, bed residency rate was 2.8 
days (MoH, 2013). 
European Gaza hospital 
 European Gaza Hospital (EGH) was established in 1999 on an area of 65 thousand 
meter squares. Located in the eastern side of Khan Yonis City, EGH provides different 
medical specialties including medical and surgical services with a total beds capacity of 246 
beds. In 2013, the total number of admitted cases was 17648 cases; bed occupancy rate was 
82.4%, bed residency rate was 4.33 days (MoH, 2013). 
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Kamal Odwan hospital 
 Kamal Odwan Hospital was established in 2002 on an area of 2.5 thousand meter 
squares.  Located in the eastern side of Beit Lahya City, the hospital provides different 
medical specialties including medical, surgical, and Obstetric and genecology services with a 
total beds capacity of 119 beds. In 2013, the total number of admitted cases was 10866 cases; 
bed occupancy rate was 83%, bed residency rate was 3.2 days (MoH, 2013). 
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 حضرة الأخ الزميل الدكتور/ ......................................................  المحترم
 تحية طيبة و بعد
و يسعدني أن أضع بين يطيب لي أن أتقدم لسيادتكم بجزيل الشكر و التقدير عمى مشاركتكم في البحث العممي الخاص بي 
مدى التزام أطباء المستشفيات الحكومية في ايديكم الإستبانة التي صممت بيدف جمع المعمومات اللازمة لمتعرف عمى 
قوم بو كمساق بحثي ضمن خطة دراستي لنيل درجة الماجستير في قطاع غزة بوصف قائمة الأدوية الأساسية و الذي أ
 الإدارة الصحية من كمية الصحة العامة في جامعة القدس أبو ديس. 
يحتوي كل سؤال من الإستبانة عمى عدة خيارات للاجابة, يرجى اختيار الاجابة التي تراىا أقرب لرأيك و ممارساتك الواقعية 
لا توجد اجابات خاطئة و أخرى صحيحة. و أن المشاركة في ىذا البحث تطوعية و لك الحق في العمل, مع الملاحظة أنو 
 في الانسحاب متى شئت.  
دقيقة من وقتكم الثمين و نستميح سيادتكم عمى ىذه المدة مع التأكيد عمى أن  51الى  01تستغرق تعبئة الاستبيانة من 
يكون ليا أية أستخدامات أخرى خارج نطاق الدراسة و أن نتائج ىذه  المعمومات الواردة في الإستبانة تعتبر سرية و لن
 الدراسة سوف تقدم لوزارة الصحة كمقترح لتطوير العمل بما يحقق تحسين جودة الخدمة المقدمة في وزارة الصحة.
 و تفضموا بقبول فائق الإحترام و التقدير
 
 الباحث                                                                              
 الخضري صالح أحمد عبد الماجد
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  .1 :التاريخ م5102......./......../       :رقـ مسمسؿ    (....................)
  .2 :المستشفي الشفاء □ ناصر □ الأوروبي □ عدوان كمال □ الأقصى □
  .3 (يمكن اختيار اكثر من واحدة)  الدرجة العممية:
 )بكالوريوس( عام طب □ عالي دبموم □  ماجستير □ دكتوراه □ زمالة/ بورد □
 /............................  حدد اخرى □ 
  .4 التخصص: باطنة □ جراحة □ أطفال □ ولادة نساء □ حروق □ عناية مركزة □
  .5 :عدد سنوات العمؿ بالمستشفى (..........) عام  
  .6 :سنوات العمؿ في جميع المستشفياتإجمالي عدد  (..........) عام  
  .7 :المسمى الإشرافي دائرة مدير □ قسم رئيس □ شعبة رئيس □ إشرافي   مسمى بلا □
  .8 :العمؿ الخاص خارج الوزارة
 خاصة عيادة □ او مستشفي  جمعية في عيادة □ جامعي تدريس □ لا يوجد □ ................/ ........حدد أخرى □
  .9 (.................) سنةمنذ متى تعمؿ في القطاع الخاص :  
 .01 خاصة بالخدمات الصحية المقدمة فيها: قائمة أدوية أساسيةفي وزارة الصحة  يوجدحسب معرفتؾ هؿ  
   نعم □  لا □ أدري لا □   
  .11 قائمة أدوية أساسية خاصة بخدماتها الصحية:  لكؿ مستشفى يوجدحسب معرفتؾ هؿ  نعم □  لا □ أدري لا □
  .21 عمى محتويات قائمة الأدوية الاساسية خلاؿ عممؾ بالوزارة: حصمت عمى تدريبهؿ  نعم □  لا □
  .31 م  ,إن وجد (..............) سنة الحصوؿ عمى التدريب:
  .41  :قائمة الأدوية الأساسية الخاصة بالوزارة يتـ تحديثحسب معرفتؾ هؿ   نعم □  لا □ أدري لا □
  .51 بشكؿ منتظـ: الخاصة بالوزارةتحصؿ عمى تحديثات قائمة الأدوية الاساسية  
  سنوي ربع □ سنوي □  سنتين كل □  تحديثات عمى أحصل لا □
  .61 يتـ بواسطة: بالوزارةقائمة الأدوية الأساسية الخاصة  تحديث
   لجنة مركزية بالوزارة فقط □ لجنة مركزية مع لجان فرعية □ لجنة موسعة عمى مستوى الوطن □ لا  أعرف □
  .71 بشكؿ منتظـ: الخاصة بالمستشفىتحصؿ عمى تحديثات قائمة الأدوية الاساسية  
  سنوي ربع □ سنوي □  سنتين كل □  تحديثات عمى أحصل لا □
  .81 يتـ بواسطة: بالمستشفىقائمة الأدوية الأساسية الخاصة  اعداد 
    المركزيةلجنة الصيدلة و العلاجيات  □ بالمستشفىلجنة الصيدلة و العلاجيات  □ المدير الطبي □ الصيدلية □ لا  أعرف □
  .91 يتـ بواسطة: بالمستشفىقائمة الأدوية الأساسية الخاصة  تحديث  
    المركزيةلجنة الصيدلة و العلاجيات  □ بالمستشفىلجنة الصيدلة و العلاجيات  □ المدير الطبي □ الصيدلية □ لا  أعرف □
  .02 قائمة الأدوية الأساسية الخاصة بػػ: اعدادشاركت في  الوزارة □ المستشفى □ كلاىما □ أشارك لم □
  .12 قائمة الأدوية الأساسية الخاصة بػػ : تحديثشاركت في  الوزارة □ المستشفى □ كلاىما □ أشارك لم □
  .22 : بالوزارة مف قائمة الادوية الاساسية الخاصة نسخةيوجد لديؾ    
 ورقية □  إلكترونية □  إلكترونية+  ورقية نسخة □ يوجد لا □
  .32 : الخاصة بالمستشفىمف قائمة الادوية الاساسية  نسخةيوجد لديؾ    
 ورقية □  إلكترونية □  إلكترونية+  ورقية □ يوجد لا □
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  محور قائمة الأدوية الأساسية (ما هو رأيؾ في الجمؿ التالية)
  .42  بالعادلةوجود قائمة الأدوية الأساسية ضروري لتقديم خدمة صحية توصف      
  .52 جودة عاليةوجود قائمة الأدوية الأساسية ضروري لتقديم خدمة صحية ذات      
  .62 المخصصة للأدوية   يقمل من ىدر الموارد الماليةوجود قائمة الأدوية الأساسية      
  .72  المريضالذي قد يصيب  يقمل من الضرروجود قائمة الأدوية الأساسية      
  .82 عممية و صحيحةاختيار الأصناف ضمن قائمة الأدوية الأساسية معايير  معايير     
  .92 المريض قد يحتاجياالأدوية التي  جميعيجب أن تشتمل قائمة الأدوية الأساسية      
  .03 اللازمة لوصف العلاج في العمل تمبي أغمب الاحتياجاتقائمة الأدوية الأساسية      
  .13 قائمة الأدوية الاساسية المتوفرة بالمستشفى ضمنأحتاج أدوية ليست في عممي      
     
بدلا من الدواء الموجود في قائمة  بشراء دواء من الصيدليات الخاصةدائما أنصح المريض 
  .23 الأدوية الأساسية
  .33 شراء الدواءمن المريض  أطمب في بعض الأدوية نقصفي حالة حدوث      
  المدرجة ضمف قائمة الأدوية الاساسية (ما هو رأيؾ في الجمؿ التالية)محور البروتوكولات العلاجية للأدوية 
  .43   مناسبةالأدوية المذكورة في البروتوكولات العلاجية المعمول بيا بالمستشفى      
  .53  تحتاج الى تحديثالبروتوكولات العلاجية المعمول بيا بالمستشفى      
  .63 خلال العمل ممزمة ليالبروتوكولات العلاجية الموجودة بالمستشفى      
  .73 للإلتزام بالبروتوكولات العلاجية المعتمدة بالمستشفى الصيدلية بحث الطبيبتقوم      
  .83 لمخدمة  يقمل من التكمفة الماليةالإلتزام بالبروتوكولات العلاجية المعتمدة بالمستشفى      
  .93 من الأدوية الأخرى أقل فاعميةالأدوية الموجودة  في البروتوكولات العلاجية      
 محور التدقيؽ و المراقبة و المتابعة (ما هو رأيؾ في الجمؿ التالية)
     
 أصناف قائمةبوصف   في المستشفى نظام متابعة و تدقيق لمعرفة مدى التزام الطبيب يوجد
  الأدوية الأساسية
  .04
  .14 بالبروتوكولاتفي المستشفى نظام متابعة و تدقيق لمعرفة مدى التزام الطبيب  يوجد     
  .24 فعال و ذو كفاءةالموجود بالمستشفى  نظام المتابعة و التدقيق     
  .34 مدى إلتزام الأطباء بالبروتوكولات العلاجية مؤشرات لقياسبالمستشفى  يوجد     
     
 عن مدى إلتزامك بالبروتوكولات العلاجية  بتغذية راجعةيتم تزويدك 
 
  .44
  .54 لأدائك الوظيفي يؤثر عمى التقييم السنويالأدوية حسب البروتوكولات العلاجية   إلتزامك بوصف     
  .64 تقوم إدارة الرقابة الداخمية بالوزارة بالتدقيق عمى الأدوية التي اقوم بوصفيا لممرضى     
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 معايير إختيار أصناؼ الأدوية ضمف قائمة الأدوية الأساسية تشمؿ: 
  .74 رأي المريض في العلاج      
  .84 نشاط شركات الأدوية و مندوبي الدعاية الطبية      
  .94 القرارات السياسية        
  .05 تكمفة العلاج      
  .15 فعالية العلاج للإستخدام      
  .25 أمان العلاج للإستخدام      
  .35 جودة العلاج       
  .45 توفر العلاج في السوق المحمية      
  .55 أن يحتوي الدواء مادة فعالة  واحدة و ليس مجموعة من المواد      
  .65 يعتمد عمى الأمراض الأكثر إنتشارأ في البمد      
    
  .75 الاساسية التي تحتاجها لعلاج المرضى خلاؿ عممؾ بالمستشفى:تقـو بإبلاغ صيدلية المستشفى بقائمة الأدوية  
   دائما □ أحيانا □ أحد أبمغ لا □ 
  .85 يوجد في العمؿ بروتوكولات علاجية معتمدة و مكتوبة:   نعم □  لا □ أعرف لا □
 .95 حدد مكاف وجود البروتوكولات العلاجية إف وجدت :    
   المستشفى مكتبة في □  القسم في □ الصيدلية في □ اعرف لا □ / .................حدد أخرى □
  .06 مصدر البروتوكولات العلاجية الموجودة بالمستشفى هو:    
 الوزارة □  المستشفى مدير □ العلاجيات و الصيدلة لجنة □ عممية مراجع و كتب □ أعرف لا □
  .16 يتوفر لديؾ رقـ هاتؼ صيدلية المستشفى: 
  فقط الداخمية □ فقط الخارجية □ الخارجية و الداخمية □  أحدا لا □
  .26 بالمستشفى بشكؿ: المتوفرة تقـو الصيدلية بإبلاغؾ بالأدوية
   يومي □ اسبوعي  □ شيري □ معمومات عمى أحصل لا □ 
  .36 في حالة عدـ توفر بعض الأدوية تقوـ الصيدلية بإبلاغؾ بالبدائؿ المتاحة لديهـ:   
  دائما □ أحيانا □ لا □   
  .46 في حالة كتابتؾ لأدوية مف خارج القائمة الأساسية تقـو الصيدلية بالإتصاؿ بؾ و ذكر البدائؿ المتاحة: 
  دائما □ أحيانا □  لا □   
  .56 بحثؾ و تشجيعؾ عمى التقيد بوصؼ الأدوية المدرجة في قائمة الأدوية الأساسية: الصيدليةتقـو  
  دائما □ أحيانا □  لا □  
  .66 تستجيب لطمب الصيدلية بكتابة الدواء المتوفرة ضمف قائمة الأدوية الأساسية: 
  دائما □ أحيانا □  لا □   
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  .76 بحثؾ و تشجيعؾ عمى التقيد بوصؼ الأدوية المدرجة في قائمة الأدوية الأساسية: إدارة المستشفىتقـو  
  دائما □ أحيانا □  لا □  
  .86 في حاؿ كنت بحاجة لمعمومة دوائية  مستعجمة  تخص الدواء تقـو بالإستعانة بػػػ:           
  المستشفى من صيدلي □ طبية دعاية مندوب صيدلي □  زميل □
  عممي مرجع في أقرأ □ TENRETNI □ /...................... حدد ىخر مصدر □
  .96 تقـو المستشفى بتنظيـ محاضرات تنشيطية خاصة بقائمة الأدوية الأساسية:  
  نعم □ لا  □  أعرف لا □  
  .07 تشارؾ في المحاضرات التنشيطية الخاصة بقائمة الأدوية الأساسية:  
  دائما □ أحيانا  □  لا □  
  .17 يقـو الصيادلة بمناقشتؾ بما يخص الدواء خلاؿ المقاء الصباحي:  
  دائما □ أحيانا □  لا □ الصباحي المقاء في الصيادلة يشارك لا □
  .27 يوجد في المستشفى لجنة صيدلة و علاجيات: 
   نعم □  لا □ أعرف لا □ 
  .37  :الخاصة بالوزارة  LDEتنسجـ مع  معتمدة و مكتوبة يصمؾ مف لجنة الصيدلة و العلاجيات بروتوكولات علاجية 
  دائما □  أحيانا □  لا □  
  .47 لحثؾ عمى الإلتزاـ بها: بتعميمات مكتوبة مف الإدارةتصمؾ البروتوكوؿ العلاجية   
   نعم □   لا □  أعرف لا □  
  .57 تقـو لجنة الصيدلة و العلاجيات بتنفيذ برنامج تدريب مستمر يخص قائمة الأدوية الأساسية بالمستشفى:  
  دائما □  أحيانا □  لا □  اعرف لا □
  .67 تقـو لجنة الصيدلة و العلاجيات بمراجعتؾ في حالة عدـ إلتزامؾ بوصؼ الأدوية المذكورة في البروتوكوؿ العلاجي:
   دائما □  أحيانا □  لا □  
  .77 يتوفر في صيدلية المستشفى الأدوية التي تقـو بوصفها: دائما □ أحيانا □ لا □ 
  .87 التي توصفها لممرضى بالمستشفى تتوفر:الأدوية  جميعيا □ بعضيا □ مطمقا تتوفر لا □
  .97 الدواء المتوفر في المستشفى ذو جودة عالية: دائما □ أحيانا □ لا □ أعرف لا □
  .08 الدواء المتوفر بالمستشفى مناسب لمحالات المرضية التي تقوـ بمعالجتها و متابعتها: 
  دائما □ أحيانا □ لا □ أعرف لا □ 
  .18 الداخمية ملاحظات عف مدى إلتزامؾ بوصؼ الأدوية مف ضمف قائمة الأدوية الأساسية:يصمؾ مف الرقابة  
   نعم □   لا □ أعرف لا □   
  .28 يزورؾ مندوبو الدعاية الطبية أثناء العمؿ (بالمستشفى و خارجها): نعم □ لا □  
  .38 زيارة مندوبي الدعاية الطبية لؾ شهريا: عدد مرات (.............) زيارة                    
  .48 مندوبي الدعاية الطبية لؾ :  مدة زيارةمتوسط  (.............) دقيقة                   
 
 البيانات الشخصية: 
  .58 الجنس: ذكر □ أنثي □   
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  .68  العمر: (...........) سنة     
  .78 الحالة الإجتماعية: أعزب □ متزوج □ ارمل □ مطمق □ 
  .88 مكاف السكف:(المحافظة) غزة شمال □ غزة □ لوسطىا المحافظات □ خانيونس □  رفح □
 
  .98 إذكر أصناؼ أدوية مف خارج قائمة الأدوية الأساسية تعتقد بضرورة إضافتها لها : 
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 …………………..…………………………………-8 .………..……………………………………………-3
 …………………..…………………………………-9 .………..……………………………………………-4
 …………………..………………………………-01 .………..……………………………………………-6
 
  .09 ما هي الأسباب التي تدفعؾ لوصؼ أدوية مف خارج قائمة الأدوية الاساسية 
  ……………………………………………………………………………………………………………… -1
  ……………………………………………………………………………………………………………… -2
  ……………………………………………………………………………………………………………… -3
  ……………………………………………………………………………………………………………… -4
  ……………………………………………………………………………………………………………… -5
 
    الخضري صالح الماجدمع تحيات الباحث: أحمد عبد  
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 cibarA ni tcartsbA
الوذرجت ضون قائوت الأدويت الأساسيت في الوستشفياث الحكىهيت في هحافظاث تقيين هذي إلتزام الأطباء بىصف الأدويت 
 قطاع غزة
 اعذاد الباحث / أحوذ عبذ الواجذ صالح الخضري
 اشراف/ د. ختام أبى حوذ
 هلخص الذراست:
يعررررررام الأطررررررف ق  مة ررررررالأ اسيررررررة بالمررررررص  م بيررررررص  م ا رررررر ص  لأ ايررررررص االأم   ررررررص  لأ رررررر  ص امرررررر     رررررراا  
ارررررص  م بيرررررص طررررر   لأسيرررررةص  لأ   رررررص قرررررم  سيررررر ا  ب      لأ ررررر ص      لأع برررررص ا المرررررص اكطا  رررررطسي  لأ   ررررر 
 م بيرررررص  م ا ررررر ص. ب  لرررررمص قس ورررررم  الأطرررررف ق اسيرررررة ا بيرررررص بالمرررررص  م بيرررررص  م ا ررررر ص  ررررر ق بخرررررس   لأسبررررر  
 لأكرررررراط  لأط   رررررر  لرررررر م خط ررررررطة قررررررم  لأمررررررايا ب رررررر ق بخررررررس   لأمعاطررررررص ب لأررررررس    لأكرررررراط  لأرررررر    مة ررررررالأ 
ه  لأ المررررص اااارررراطص  لأرررر   رررر ق بخررررس   لأ ررررص   خرررر  قعطمرررر  قكطررررس  ا  ررررا   مة ررررالأ. ام طسيررررا  ب اهم ررررص هرررر 
بيمثررررص  اوةرررراص  طرررر   لأ رررر ص ب ءرررر   قرررري ا  ررررا اخررررف لأ  اوةرررراص  الأم ررررا  ب  طرررر  ق ررررطس   لأعررررالأ  يررررط  اوةرررراص قررررا 
يفيررررر   ررررري  تررررر م  ايط سورررررا   با  اقايكررررر   طررررر   لأ ررررر ص  ررررر سيا. ب طررررر  اءررررر   لأط ررررر يا    لأمط ة رررررص يرررررط  
٪ قررررري  لأمرررررس     لأ ررررر  ص  ب  مثرررررص  م بيرررررص اءررررر   لأث ترررررص ا رررررس   م ثرررررا  ررررر س ا طررررر  23-21ا قع لأرررررة  اهررررر    قررررر
 اهررررر    ب ررررر ق  ةرررررالأ   لأ  ررررراق  لأ ررررر   ب ب رررررس ه  ررررري   ررررر ي   لأ ررررر قا   لأم طسارررررص ق رررررة. ب يمكررررري ا  يكرررررس  
 ب رررررس  ا  لأ  لأ  ررررراق  لأ ررررر   ا ررررر    اوةررررراص ص رررررا  لأكررررراط   طررررر   لأ ررررر قا   لأ ررررر  ص اب  اوةررررراص  لأف لررررر  ص رررررا
 لأم ررررا . ب يعط ررررا  ررررطسي  مة ررررالأ طرررر  بيررررة  م بيررررص ا ررررس   ص ررررا   رررر    لأررررة  رررر ت ا  ررررط    طرررر   لأمررررس    
 لأ   رررررص ب يررررر  ا الأررررر   لأطكرررررالأ ة  لأمالأ رررررص  لأف لررررر   ص رررررا  لأم رررررا    ط ررررر   ررررري   ترررررا   لأ ررررر  ص ص رررررا  لأماصرررررس  
ل    لأطرررررر  ط هرررررا  طررررر   لأمااررررر . ب يعررررر   عفيرررررف  ا رررررط   ق  لأا رررررر   لأطمرررررس     لأ ب ل رررررص  لأمطاءرررررص قررررري  لأمررررر  
 ٪ قي اخمالأ   لأ ة ا   لأ   ص لأط ط   .5يمك ها  سط ا قا ي ص  لأ  
 لأطمسيرررررص قررررري  ارررررمي  لأ ررررر اص  لأررررر ا  ع لرررررة طط ررررر  ي   عطمررررر   لأ رررررط ص  لأسة  رررررص  لأةط ررررر    ص   طمرررررا    ط رررررا  طررررر 
وةرررررق  لأسبررررر  طرررررئ   لأ  رررررا   ا رررررا ل ط   لأم رررررطما ب اءرررررط م بررررر  اارررررعةا  لأ  ررررراق   لأدهرررررا   لأماو رررررص ب طررررر 
اررررالأس     طرررر    م بيررررص  لأما فيررررص لأرررر   ق ررررطس  ا   لأةط رررر     ء ررررز بيررررص ق ررررفب   م بيررررص لأ رررر   
  لأم اط ررررررررررا   لأد سا ررررررررررص  لأرررررررررر  ا ورررررررررر  ق ررررررررررطس  قرررررررررري  لأرررررررررر    لأرررررررررر ا لأرررررررررر  ي رررررررررر   لأررررررررررة قث رررررررررررص.
 هن الذراست:  الهذف
 لأهررررر م  لأعررررراق قررررري هررررر ه  لأ    رررررص هرررررس    ررررر   قررررر   الأطرررررف ق  مة رررررالأ  لأعررررراقط ي طررررر  ق طلرررررة ا  ب      لأ ررررر ص  
 بيص قي بالمص  م بيص  م ا  ص  لأمعطم   لأ    لأس    .اسية  م 
 هنهجيت الذراست:
 لأ    رررررص   رررررا    ررررري     رررررص بيرررررة ص   ط ط رررررص  رررررمط   لأ  اورررررا   لأكم رررررص.  ررررر  خمرررررم  لأ  اورررررا  ائ رررررط   ق ا اعرررررص 
ا ب   اباهرررررا ا رررررط اوص يرررررط   ع  طهرررررا اس  ررررر ص  مة رررررالأ ااااررررراطص  لأررررر  ت ترررررص برررررس ل  ط ررررر   رررررط اطررررر بيي 
  141
 
لأطرررررر  برررررراق  مة ررررررالأ اسيررررررةها طرررررر   رررررر   ا  ا ررررررط  ام ب  لأ ررررررس    ب  رررررر   ا  لأماارررررر   لأم ررررررسق ي ب  م بيررررررص  
  رررررط اوص     رررررص  لأطع  رررررص قررررري  291طررررر   لأمدمرررررس    ررررر  خمرررررم  االأم طلرررررة ا .   لأمااررررر   لأم رررررسق يلرررررابج  ررررر   ا 
 ررررررررر  ا   2111 ررررررررر  ا  ب ررررررررر    رررررررررط  ام ب ةرررررررررس     ب  5951 ررررررررر  ا  قرررررررررايا ق رررررررررسق ب  1921 مة رررررررررالأ  
 رررررر    ط ررررررص  لأ  اوررررررا  اا ررررررط   ق ااورررررراقح  لأ فقررررررص  اء ررررررال ص لأطعطررررررسق  اخطما  ررررررص  لررررررابج قررررررايا ق ررررررسق .
طررررررا     ب لأ  رررررر   لأم سيررررررص   لأدرررررر  بم   مررررررا ء رررررر    لأ  رررررر   لأم سيررررررص ) ء ررررررز اخايرررررر   لأطس يعررررررا    لأ)SSPS
 ايدا   لأع با  ا ي  لأمطغ ا  . erauqS-ihC لأمطس  ص ب لأعاقص بخ  بم  لأمط اةعص ب      ط   ق 
 أهن النتائج:
باظهررررررا  وطررررررالح  لأ    ررررررص ا  قطس رررررري  رررررر    م بيررررررص  لأطرررررر   سيررررررة طرررررر   رررررر   ا  ب لأ  لأماارررررر   لأم ررررررسق ي 
٪)  اورررررر  قطس ط ررررررص 18 لأ طرررررر   ررررررص ومررررررس ج   ب لأغالأ  ررررررص  لأع مرررررر  قرررررري هرررررر ه  لأ مررررررا ج   ب 11.5اطغرررررر  قعرررررر م 
باطررررو قطس رررري  رررر    م بيررررص  لأطرررر   رررر  بيررررةها    ماقررررا قررررم بالمررررص  م بيررررص  م ا رررر ص  لأ ايررررص اررررس      لأ رررر ص.
٪)  14 ب لأ لأكررررررص   ايررررررا   ب تطررررررز هرررررر ه  لأط ررررررا يا   81.1طرررررر    ررررررا يا ب رررررر   ا ررررررط  ام ب  لأ ررررررس    قعرررررر م 
 رررررص  ماقرررررا قرررررم بالمرررررص  م بيرررررص  م ا ررررر ص  لأ ايرررررص ارررررس      لأ ررررر ص. باطرررررو قطس ررررري  ررررر    م بيرررررص  اوررررر  قطس ط
ا بيرررررص لأكرررررص   ايرررررا  ب قرررررا ي رررررا  قررررري تطرررررز  4 لأطررررر  بيرررررة  طررررر    رررررا يا لرررررابج  لأمااررررر   لأم رررررسق ي قعررررر م 
 ٪)  او  قطس ط ص  ماقا قم بالمص  م بيص  م ا  ص  لأ ايص اس      لأ  ص.14ه ه  لأط ا يا  
وطرررررالح  لأ    رررررص ا  ق رررررطس  قعاطرررررص  مة رررررالأ  لأملرررررا   ي ط هرررررا  ررررري بالمرررررص  م بيرررررص  م ا ررررر ص ببررررر  اظهرررررا  
 لأ ايررررررص اررررررالأس     ب بالمررررررص  م بيررررررص  لأ ايررررررص االأم طلررررررة  ب مط ررررررص   رررررر يثهما لأ  رررررر   الأ ررررررص. بقررررررم  لأرررررر   
 ه رررراي قسبررررة ايدرررراا  ارررر ي  مة ررررالأ ءررررسم بالمررررص  م بيررررص  م ا رررر ص ب طالرررر  ها. ب  ةرررر  صالأ  ررررص  لأملررررا   ي طرررر 
 لأ    رررررص  طررررر  اهم رررررص بالمرررررص  م بيرررررص  م ا ررررر ص لأطرررررسط ا لررررر قا  يررررر  ص  ا لأرررررص  لأط ررررر ي  لررررر قا  يررررر  ص     
خررررس    لأط رررر  قرررري هرررر   طرررر   لأمررررس     لأمالأ ررررص  لأط رررر  قرررري ءرررر بم اررررا  لأطمررررايا  ب اخمعررررس   طرررر  ء   ررررص ا  
لح ا   لط ررررررا   م بيررررررص  لأم  خررررررص بالمررررررص  م بيررررررص  م ا رررررر ص  يررررررط   طرررررر  ا ررررررق  طم ررررررص. ب برررررر  اظهررررررا   لأ طررررررا
صالأ  رررررررص  لأملرررررررا   ي طررررررر   لأ    رررررررص لأ  رررررررس   طررررررر   س يرررررررص قرررررررم يررررررر ا لأص  لأم طلرررررررة  الررررررركص يررررررر    با 
ب لرررررة   .ي رررررطد  س  لأطسيررررر ا   لأ ررررر ا لأص  لأ ايرررررص اطعفيرررررف بيرررررة  م بيرررررص قررررري بالمرررررص  م بيرررررص  م ا ررررر ص
يرررررص وطرررررالح  لأ    رررررص ا  ا      لأم طلرررررة  ا  مرررررا ج  ب هرررررا اكةرررررالأ  طررررر   لرررررد م  مة رررررالأ لأ لأطرررررف ق اسيرررررة ا ب
 بالمص  م بيص  ا ا  ص . 
  الخلاصت:
ه ررررراي ءاخرررررص قا رررررص  لأررررر  اخرررررا لأ  لأمفيررررر  قررررري  لأ    رررررا  ب ما رررررام  امرررررا طررررر   لأررررر   اا رررررام      لأ ررررراام 
 لأكمرررر  اااارررراطص  لأرررر   ما ررررام  لأ س  ررررص      لأةهرررر   م رررر  لأدم ررررم  لأعس قررررص      لأ ررررطص  لأطرررر  برررر   رررر تا  طرررر  
 ا ا رررررر ص. به رررررراي اي ررررررا ءاخررررررص اخررررررا لأ  لأ  ررررررسم  قرررررر   الأطررررررف ق  مة الأاسيررررررة ا بيررررررص بالمررررررص  م بيررررررص
 ب لأ    ا   لأمماتطص ط   لأم طلة ا   لأ كسق ص اءا يص  لأط   ب   لأ   لأم طلة ا   لأ ايص.
 .………………
